var title_f40_34_41504="Ketorolac: Patient drug information";
var content_f40_34_41504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketorolac: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/59/41909?source=see_link\">",
"       Ketorolac (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=see_link\">",
"       Ketorolac (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3606?source=see_link\">",
"       Ketorolac (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10783 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-115.124.72.62-8E1C3CC7B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41504=[""].join("\n");
var outline_f40_34_41504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41505="Postauricular lymph node";
var content_f40_34_41505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postauricular lymphadenopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postauricular lymph node in a child with tinea capitus and kerion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41505=[""].join("\n");
var outline_f40_34_41505=null;
var title_f40_34_41506="Patient information: How to use your metered dose inhaler (adults) (The Basics)";
var content_f40_34_41506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16113\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37439\">",
"         Metered dose inhaler",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\">",
"          Accessory devices used with metered dose inhalers",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/55/4991\">",
"           MDI with counter",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/11/4275\">",
"         Patient information: Asthma in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/47/9970\">",
"         Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/43/30386\">",
"         Patient information: Inhalers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/22/30052\">",
"         Patient information: Medicines for asthma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/25/29075\">",
"         Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/63/39925\">",
"         Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/how-to-use-your-metered-dose-inhaler-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17353396\">",
"      <span class=\"h1\">",
"       Do I need to do anything to get my inhaler ready?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The first time you use your inhaler, you need to get it ready. To do this, you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take the cap off the mouthpiece",
"       </li>",
"       <li>",
"        Shake the inhaler for 5 seconds (",
"        <a class=\"graphic graphic_picture graphicRef61575 \" href=\"mobipreview.htm?36/35/37439\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Press down on the canister to spray the medicine into the air (away from your face)",
"       </li>",
"       <li>",
"        Repeat these steps 3 more times",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you haven&rsquo;t used your inhaler for more than 2 weeks, you should do the steps above before you use it.",
"     </p>",
"     <p>",
"      After your inhaler is ready, you can use it as prescribed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353403\">",
"      <span class=\"h1\">",
"       How do I use my inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each inhaler has its own directions. Your doctor or nurse will show you how to use yours. In general, to use a metered dose inhaler, you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take the cap off the mouthpiece.",
"       </li>",
"       <li>",
"        Shake the inhaler for 5 seconds.",
"       </li>",
"       <li>",
"        Hold the inhaler upright with your finger on the top of the canister and your thumb holding the bottom of the inhaler.",
"       </li>",
"       <li>",
"        Breathe out a normal breath.",
"       </li>",
"       <li>",
"        Close your lips around the mouthpiece, or hold the mouthpiece 1 to 2 inches (4 cm) in front of your mouth.",
"       </li>",
"       <li>",
"        As you start to inhale the next breath, press down on the canister.",
"       </li>",
"       <li>",
"        Keep inhaling deeply and slowly through your mouth.",
"       </li>",
"       <li>",
"        When your lungs are full, hold your breath for 5 to 10 seconds to keep the medicine in your lungs.",
"       </li>",
"       <li>",
"        Let your breath out.",
"       </li>",
"       <li>",
"        If you are supposed to take 2 puffs of your inhaler, wait 15 to 30 seconds before you take the second puff. Shake the inhaler again before the second puff.",
"       </li>",
"       <li>",
"        Put the cap back on the mouthpiece.",
"       </li>",
"       <li>",
"        If you use a &ldquo;glucocorticoid&rdquo; (steroid) inhaler, rinse your mouth out with water, gargle, and spit out the water.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353410\">",
"      <span class=\"h1\">",
"       What if I have trouble pressing on the canister and breathing in?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have trouble pressing down on the canister and breathing in at the same time, let your doctor or nurse know. He or she can prescribe a:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Different metered dose inhaler &mdash; One kind of metered dose inhaler works in a different way. It sprays medicine when a person takes a deep breath, instead of when he or she presses down on the canister.",
"       </li>",
"       <li>",
"        Spacer &mdash; A spacer is a device that attaches to the inhaler&rsquo;s mouthpiece (",
"        <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"         picture 2",
"        </a>",
"        ). When a person presses down on the canister, the medicine sprays into the spacer and sits there until he or she breathes it in.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353417\">",
"      <span class=\"h1\">",
"       How do I use an inhaler with a spacer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To use an inhaler with a spacer, follow the general directions above. But before you press down on the canister, close your lips around the spacer&rsquo;s mouthpiece. After you press down on the canister, breathe in deeply and slowly, and hold your breath for 5 to 10 seconds. Let your breath out. Then breathe in again and hold your breath for 5 to 10 seconds.",
"     </p>",
"     <p>",
"      Some spacers let you know if you breathe in too fast by making a whistle noise. If you hear a whistle noise when you breathe in, make sure to breathe in more slowly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353424\">",
"      <span class=\"h1\">",
"       Do I need to clean my inhaler?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you use your inhaler every day, clean it at least once a week. If you don&rsquo;t use your inhaler every day, you can clean it less often. To know when you need to clean it, look inside the mouthpiece. Clean your inhaler when you see powder in or around the hole.",
"     </p>",
"     <p>",
"      To clean an inhaler, you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Remove the canister and cap from the mouthpiece. Do not wash the metal canister or put the canister under water.",
"       </li>",
"       <li>",
"        Run warm water through the mouthpiece for 30 to 60 seconds.",
"       </li>",
"       <li>",
"        Shake the water off of the mouthpiece and let it air-dry overnight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353431\">",
"      <span class=\"h1\">",
"       Do I need to clean my spacer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you use an AeroChamber spacer every day, clean it every 1 to 2 weeks (",
"      <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"       picture 2",
"      </a>",
"      ). Wash it with warm water and dishwashing soap, rinse it, and let it air-dry. Do not put it in the dishwasher.",
"     </p>",
"     <p>",
"      If you use an InspirEase chamber every day, replace the bag every 1 to 2 weeks (",
"      <a class=\"graphic graphic_picture graphicRef56533 \" href=\"mobipreview.htm?21/27/21951\">",
"       picture 2",
"      </a>",
"      ). Clean the mouthpiece in warm water, rinse it, and let it air-dry. Do not wash the bag.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353438\">",
"      <span class=\"h1\">",
"       How do I know if my inhaler is empty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some inhalers come with a built-in dose counter (",
"      <a class=\"graphic graphic_picture graphicRef69302 \" href=\"mobipreview.htm?4/55/4991\">",
"       picture 3",
"      </a>",
"      ). A counter keeps track of how many doses are left in your inhaler.",
"     </p>",
"     <p>",
"      When the counter reads 0 (zero), it&rsquo;s time to throw out the inhaler because it has no more medicine in it. Make sure to have another inhaler on hand before the counter reads 0.",
"     </p>",
"     <p>",
"      If your inhaler doesn&rsquo;t have a built-in counter, you need to keep track of the number of doses left in your inhaler. Based on how often you use your inhaler, you can figure out when you will need a refill and write this date down.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17353445\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=see_link\">",
"       Patient information: Asthma in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=see_link\">",
"       Patient information: Inhalers (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=see_link\">",
"       Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=see_link\">",
"       Patient information: Medicines for asthma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=see_link\">",
"       Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=see_link\">",
"       Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/34/41506?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16113 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41506=[""].join("\n");
var outline_f40_34_41506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353396\">",
"      Do I need to do anything to get my inhaler ready?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353403\">",
"      How do I use my inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353410\">",
"      What if I have trouble pressing on the canister and breathing in?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353417\">",
"      How do I use an inhaler with a spacer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353424\">",
"      Do I need to clean my inhaler?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353431\">",
"      Do I need to clean my spacer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353438\">",
"      How do I know if my inhaler is empty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17353445\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/35/37439\">",
"      Metered dose inhaler",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/27/21951\">",
"       Accessory devices used with metered dose inhalers",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/55/4991\">",
"        MDI with counter",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/47/9970?source=related_link\">",
"      Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41507="First-line medical treatment of epithelial ovarian cancer";
var content_f40_34_41507=[" <h1 id=\"patTopicTitle\">",
"  Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/34/41507/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41507/contributors\" id=\"au1171\">",
"       Thomas J Herzog, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41507/contributors\" id=\"au5528\">",
"       Vincent E Herrin, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/34/41507/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41507/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/34/41507/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41507/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/34/41507?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVARIAN CANCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cancer is the ninth most common of all types of cancer and the second most common cancer of the reproductive organs among women in the United States [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/34/41507/abstract/1\">",
"      1",
"     </a>",
"     ]. The average age at diagnosis of ovarian cancer is 63 years-old [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/34/41507/abstract/2\">",
"      2",
"     </a>",
"     ]. The lifetime risk of developing ovarian cancer is approximately 1.4 percent.",
"    </p>",
"    <p>",
"     There are several different types of cancer that can arise in the ovary, although epithelial ovarian cancer (referred to as ovarian cancer in this topic) is the most common and is the subject of this review.",
"    </p>",
"    <p>",
"     This topic review will cover chemotherapy treatment for ovarian cancer. Separate topic reviews are available that discusses the diagnosis and staging (including initial surgical staging) of ovarian cancer. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=see_link\">",
"      \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      DO I NEED CHEMOTHERAPY?",
"     </span>",
"    </p>",
"    <p>",
"     After ovarian cancer is removed with surgery, there is still a risk that cancer cells remain and may return or spread to other parts of the body. Chemotherapy is given after surgery to destroy these cells and improves the chance of curing ovarian cancer and decreases the risk of dying of ovarian cancer. The need for chemotherapy depends on the disease stage, which is determined at the time of surgery. In general, chemotherapy is recommended for all newly diagnosed patients except in the case of selected women with stage IA or IB disease (also called &ldquo;early stage disease&rdquo;). For women diagnosed with early stage disease, surgery alone is effective, and no additional therapy is recommended. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=see_link&amp;anchor=H9#H9\">",
"      \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\", section on 'Staging'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      What is chemotherapy?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy refers to the use of medicines to stop or slow the growth of cancer cells. Chemotherapy works by interfering with the ability of rapidly growing cells (such as cancer cells) to divide or reproduce themselves. Because most of an adult's normal cells are not rapidly growing, they are not as affected by chemotherapy. Exceptions to this include rapidly dividing cells such as bone marrow (where the blood cells are produced), hair, and lining of the gastrointestinal tract; thus chemotherapy results in side effects such as low blood counts and hair loss.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31265057\">",
"     <span class=\"h2\">",
"      What types of chemotherapy are used?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Among the chemotherapy agents most commonly used in the treatment of ovarian cancer are taxanes (paclitaxel or docetaxel) and platinum agents (carboplatin or cisplatin). Studies have demonstrated that platinum and taxane-containing chemotherapy improves the survival of women with ovarian cancer over other types of regimens. As a result, the combination of a platinum-type drug (usually carboplatin) and a taxane (typically paclitaxel) is a standard chemotherapy regimen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31264574\">",
"     <span class=\"h2\">",
"      How is chemotherapy administered?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most chemotherapy drugs is given into the vein (intravenously or IV). However, for women with optimally resected stage III disease, another treatment strategy involves giving a combination of chemotherapy both IV and directly into the abdominal (peritoneal) cavity, called intraperitoneal (IP) chemotherapy",
"     <span class=\"nowrap\">",
"      (IV/IP",
"     </span>",
"     treatment).",
"    </p>",
"    <p>",
"     In general, regardless of the route administered (intravenously or intraperitoneally), chemotherapy drugs are given in a carefully defined sequence and doses over a period of several months. Chemotherapy drugs are usually not administered daily but periodically, in cycles. A cycle of chemotherapy refers to the time it takes to give the treatment and then allow the body to recover from the effects. During this time, patients are closely monitored for signs of drug toxicity and side effects.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31264731\">",
"     <span class=\"h2\">",
"      Influence of disease stage on the chemotherapy recommendation",
"     </span>",
"     &nbsp;&mdash;&nbsp;As noted above, the need for chemotherapy after surgery and the type and duration of treatment that is recommended depends on the disease stage and aggressiveness of the tumor (also referred to as the &ldquo;grade&rdquo; of the tumor). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=see_link&amp;anchor=H9#H9\">",
"      \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\", section on 'Staging'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31264763\">",
"     <span class=\"h3\">",
"      Stage I",
"     </span>",
"     &nbsp;&mdash;&nbsp;After surgery, most women with stage IA or IB ovarian cancers (ie, cancers limited to the ovary) do well without chemotherapy, and observation alone is a standard approach. Women with aggressive (grade 2 or 3) stage IA or IB ovarian cancers and all women with stage IC ovarian cancer should receive chemotherapy after surgery using paclitaxel and carboplatin. Treatment usually begins within two to six weeks after surgery. Each cycle of chemotherapy is given over three weeks for a total of six cycles. However, the optimal duration of chemotherapy for women with stage I ovarian cancer remains controversial. Many oncologists recommend individualizing the number of cycles (with a minimum of three) based upon patient risk factors and how well the woman is tolerating the chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31264801\">",
"     <span class=\"h3\">",
"      Stage II",
"     </span>",
"     &nbsp;&mdash;&nbsp;All women with stage II disease (ie, outside the ovary but confined to the pelvis) require chemotherapy after surgery. Most oncologists administer six cycles of intravenous paclitaxel plus carboplatin. Some clinicians also use a combination of intraperitoneal and intravenous chemotherapy for women with stage II disease, but there is no evidence that the benefits of",
"     <span class=\"nowrap\">",
"      IV/IP",
"     </span>",
"     treatment in women with stage II ovarian cancer is more beneficial than standard administration of IV chemotherapy alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31264857\">",
"     <span class=\"h3\">",
"      Stage III",
"     </span>",
"     &nbsp;&mdash;&nbsp;All women with stage III disease (ie, abdominal involvement) require chemotherapy after surgery. In the United States, the standard course of chemotherapy can be given in different methods:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Six cycles of paclitaxel plus carboplatin given on day 1 of a 21-day cycle. This treatment approach has been a standard approach for many years. Some studies suggest that adding another drug, bevacizumab (given every three weeks during chemotherapy and then for one year after), to this regimen may postpone relapse. No data to date have shown that adding bevacizumab improves overall survival.",
"      </li>",
"      <li>",
"       Six cycles of carboplatin on day 1 with paclitaxel on days 1, 8, and 15 of a 21-day cycle. This &ldquo;dose-dense&rdquo; treatment approach is preferred by some clinicians based upon one randomized trial that showed an improvement over time to relapse and overall survival when compared with every 21 day paclitaxel plus carboplatin. However, &ldquo;dose-dense&rdquo; chemotherapy is associated with more toxicity than every 21-day administration.",
"      </li>",
"      <li>",
"       Six cycles of a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy. In this 21-day schedule, cisplatin is given IP on day 1, paclitaxel on day 1 or day 2 as an IV infusion, and then paclitaxel is given IP on day 8. This",
"       <span class=\"nowrap\">",
"        IV/IP",
"       </span>",
"       regimen is preferred by some clinicians based upon several randomized trials that have shown an improvement in time to relapse and overall survival when compared with IV therapy alone. However,",
"       <span class=\"nowrap\">",
"        IV/IP",
"       </span>",
"       chemotherapy requires placement of an IP catheter (either during the initial surgery or as a second outpatient surgical procedure) and is associated with significant toxicity, which many patients cannot tolerate.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31265020\">",
"     <span class=\"h3\">",
"      Stage IV",
"     </span>",
"     &nbsp;&mdash;&nbsp;All women with stage IV disease (ie, commonly involving the lungs or liver) require chemotherapy. Women who present with stage IV ovarian cancer cannot be cured. Instead, the chemotherapy is given to control cancer growth. In this case, carboplatin and paclitaxel are typically administered as long as the chemotherapy is tolerated and a benefit is seen. This may require more than six cycles of chemotherapy. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31265136\">",
"     <span class=\"h2\">",
"      What are the side effects of treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemotherapy can cause side effects during and after treatment. The type and severity of these side effects depends upon which chemotherapy drugs are used and how they are administered. Side effects that occur during chemotherapy are usually temporary and reversible. The most common side effects are nausea, vomiting, mouth soreness, temporary lowering of the blood counts, and hair loss.",
"    </p>",
"    <p>",
"     Bevacizumab can cause side effects that are different from those caused by chemotherapy. Common side effects include new or worsening hypertension, nose bleeds, dizziness, headache, and delayed wound healing. Women with ovarian cancer who receive bevacizumab may have a slightly increased risk of bowel perforation during treatment. Patients with preexisting tumor involvement of the gastrointestinal tract (eg, bowel obstruction or bowel wall thickening) or history of inflammatory bowel disease appear to be at greatest risk for this complication. Although initial studies suggested that this was relatively common, subsequent studies suggest that the overall risk is 7 percent or less.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31264588\">",
"     <span class=\"h1\">",
"      SPECIAL CONSIDERATIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Neoadjuvant chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, chemotherapy is given after surgery for ovarian cancer. Occasionally, it is too risky to perform initial surgery because of the extensive nature of the cancer",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the debilitated condition of the patient. In such cases, chemotherapy may be recommended as a first step in the treatment process; this is referred to as neoadjuvant chemotherapy. Initial or neoadjuvant chemotherapy can shrink the tumor and improve a woman's overall medical condition, making her a better candidate for later debulking surgery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      SURVEILLANCE AFTER OVARIAN CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     At the end of treatment (both surgery and chemotherapy), a woman is considered to have a \"complete response\" if her physical examination is normal, there is no evidence of cancer on imaging studies (such as a CT scan), and the blood levels of the tumor marker CA-125 are normal. However, even when all of these criteria are met, microscopic amounts of residual cancer (ie, not visible on imaging studies) can still be present. Growth of these microscopic tumor cells is probably responsible for tumor recurrence at a later date.",
"    </p>",
"    <p>",
"     To monitor for the possibility of recurrent ovarian cancer, follow-up blood tests, physical examinations, and imaging tests are recommended for at least five years after treatment ends. Though optimal surveillance strategy is not defined, our approach is similar to the guidelines from the National Comprehensive Cancer Network (NCCN):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Office visits with pelvic examination every two to four months for two years, then every six months for three years, then annually.",
"      </li>",
"      <li>",
"       Periodic blood tests for CA-125",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       HE4 at the discretion of your physician. A rise in the level of blood tumor markers such as these is often the earliest sign of an ovarian cancer recurrence. However, the benefit of detecting and treating a recurrence based on elevations in tumor makers alone, before there are any signs or symptoms of recurrence, has been questioned. (See",
"       <a class=\"local\" href=\"#H14\">",
"        'Signs of recurrence'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Chest X-ray and",
"       <span class=\"nowrap\">",
"        chest/abdomen/pelvic",
"       </span>",
"       CT scan are reserved for patients with any abnormalities on history, exam, or blood test.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Signs of recurrence",
"     </span>",
"     &nbsp;&mdash;&nbsp;Even women with a complete response to initial therapy can have a recurrence of ovarian cancer at a later time. The likelihood of a tumor recurrence is highest in women with more advanced-stage disease at diagnosis, particularly if the initial debulking surgery was unable to remove all visible tumor. The earliest evidence of recurrent ovarian cancer can be indicated by a rising blood level of one of the tumor markers (CA-125 or HE4), symptoms (often abdominal pain or bloating with or without back pain), or clinical signs (bloating or a pelvic mass).",
"    </p>",
"    <p>",
"     In the past, treatment for recurrent ovarian cancer was sometimes recommended based on rising levels of tumor markers alone, instead of waiting until symptoms developed. However, a large study showed no survival benefit of starting chemotherapy based on a high level of CA-125 and that quality of life may be improved by waiting until there are symptoms or signs of ovarian cancer recurrence. You should talk to your healthcare provider for more information about this issue.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H501915373\">",
"     <span class=\"h1\">",
"      DIAGNOSIS OF RECURRENT OVARIAN CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Women with recurrent ovarian cancer following an initial complete response and those who do not respond well to initial chemotherapy are candidates for further chemotherapy, often called second-line chemotherapy. The choice of chemotherapy agents for second-line treatment depends upon whether and how well, the patient responded to first-line treatment, current symptoms, time elapsed from last treatment, and long term side-effects from previous chemotherapies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31265145\">",
"     <span class=\"h2\">",
"      Platinum-sensitive ovarian cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a woman had a complete response, and the response lasted for at least six months, she is considered to have &ldquo;platinum-sensitive&rdquo; cancer and re-treatment with platinum-based chemotherapy is usually recommended. Studies show that a repeat response to chemotherapy is possible with platinum-based re-treatment. In fact, if the initial response lasted longer than 24 months, up to one-fourth of patients will have a complete response to re-treatment with platinum. Suitable regimens include carboplatin with either a taxane, gemcitabine, or pegylated liposomal doxorubicin. The addition of bevacizumab to the combination of carboplatin and gemcitabine in particular was associated with an improvement in both response rate and time to progression in a large randomized trial.",
"    </p>",
"    <p>",
"     Studies in carefully selected patients have also demonstrated a benefit to repeat surgical treatment, particularly if the tissue can be easily removed and the woman has been free of disease recurrence for more than 6 to 12 months. Thus, repeat surgical treatment may be an option.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31265152\">",
"     <span class=\"h2\">",
"      Platinum-resistant ovarian cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a woman has persistent or non-responsive ovarian cancer despite first-line therapy with paclitaxel and a platinum agent, or if she relapses within six months of completing such therapy, she is considered to have &ldquo;platinum-resistant&rdquo; cancer. In this case, treatment with a single chemotherapy agent is recommended as combination chemotherapy has not improved either response rates or survival, but is associated with an increased risk of toxicity. A variety of agents may be considered, including pegylated liposomal doxorubicin, topotecan, docetaxel, oral etoposide, gemcitabine, vinorelbine, ifosfamide, leucovorin-modulated 5-fluorouracil, bevacizumab, and tamoxifen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Patients should strongly consider enrollment on a trial and available studies should be discussed with your physician. Read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"        www.cancer.gov/clinicaltrials/learning/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784784120\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5513310\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=see_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/27/39346?source=see_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/14/27874?source=see_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=see_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5513318\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=see_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33033?source=see_link\">",
"      Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10474?source=see_link\">",
"      Screening for ovarian cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29977?source=see_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17224?source=see_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23927?source=see_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26231?source=see_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28070?source=see_link\">",
"      Surgery for recurrent epithelial ovarian cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25847?source=see_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Ovarian Cancer Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ovarian.org/\">",
"      www.ovarian.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/34/41507?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41507/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on May 26, 2011).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_34_41507=[""].join("\n");
var outline_f40_34_41507=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVARIAN CANCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           DO I NEED CHEMOTHERAPY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31264588\">",
"           SPECIAL CONSIDERATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           SURVEILLANCE AFTER OVARIAN CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H501915373\">",
"           DIAGNOSIS OF RECURRENT OVARIAN CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41508="Fluoxymesterone: Drug information";
var content_f40_34_41508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoxymesterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/61/18388?source=see_link\">",
"    see \"Fluoxymesterone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/46/18147?source=see_link\">",
"    see \"Fluoxymesterone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Androxy&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Androgen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypogonadism (Males):",
"     </b>",
"     Oral: 5-20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Delayed puberty (Males):",
"     </b>",
"     Oral: 2.5-20 mg daily for 4-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inoperable breast carcinoma (Females):",
"     </b>",
"     Oral: 10-40 mg daily in divided doses for &ge;3 months",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androxy&trade;: 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F172840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15863712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Males: May be administered in single or divided doses. Females: Adjminister in divided doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy in the treatment of delayed male puberty; male hypogonadism (primary or hypogonadotropic); inoperable metastatic female breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Halotestin [Great Britain] may be confused with Haldol brand name for haloperidol [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Male:",
"     </b>",
"     Gynecomastia, oligospermia (at higher doses), priapism, prostatic carcinoma, prostatic hypertrophy, testicular atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female:",
"     </b>",
"     Menstrual irregularities (including amenorrhea), virilism (including deepening of the voice, clitoris hypertrophy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, hirsutism, &ldquo;male pattern&rdquo; baldness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte abnormalities (sodium, chloride, calcium, potassium, and inorganic phosphate retention), hypercholesterolemia, libido changes (increased or decreased), water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Prostatic hyperplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Clotting factor suppression, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic coma (rare), hepatic dysfunction, hepatocellular neoplasms (rare), liver function tests abnormal, peliosis hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Males with carcinoma of the breast or the prostate (known or suspected); women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyslipidemia: Anabolic steroids may alter serum lipid profile; use caution in patients with history of myocardial infarction or coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gynecomastia: May cause gynecomastia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Prolonged use of high doses of oral androgens has been associated with serious hepatic effects (eg, peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Discontinue use in patients with cholestatic hepatitis with jaundice or abnormal liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Use with caution in patients with breast cancer or immobilization; may cause hypercalcemia by stimulating osteolysis. Discontinue use if hypercalcemia occurs; may indicate bony metastasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Elderly patients may be at greater risk for prostatic hyperplasia and prostate cancer; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May accelerate bone maturation without producing compensatory gain in linear growth in children. In prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: During treatment for metastatic breast cancer, women should be monitored for signs of virilization (eg, deepening of voice, hirsutism, acne, clitoromegaly, menstrual irregularities); discontinue use with evidence of mild virilization to prevent irreversible symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in women who are or may become pregnant. May cause androgenic effects to the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fluoxymesterone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5686408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Androxy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $577.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, lipid panel, hemoglobin, and hematocrit (prior to therapy, at 3-6 months, then annually); radiologic examination of wrist and hand every 6 months (when using in prepubertal children). Withhold initial treatment with hematocrit &gt;50% (discontinue therapy if hematocrit exceeds 54% [Bhasin, 2010]), hyperviscosity, untreated obstructive sleep apnea, or uncontrolled severe heart failure. Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone; monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3-6 months after initiation and then annually.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afluteston (AT);",
"     </li>",
"     <li>",
"      Baojen (TW);",
"     </li>",
"     <li>",
"      Fuloan (TW);",
"     </li>",
"     <li>",
"      Halotestin (AE, AU, BF, BH, BJ, CI, CY, EG, ET, FR, GH, GM, GN, GR, HU, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NO, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Oralsterone (TW);",
"     </li>",
"     <li>",
"      Sidomon (TW);",
"     </li>",
"     <li>",
"      Stenox (MX);",
"     </li>",
"     <li>",
"      Vewon (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic derivative of testosterone; responsible for the normal growth and development of male sex hormones, male sex organs, and maintenance of secondary sex characteristics; large doses suppress endogenous testosterone release",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10 hours (range: 10-100 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%); feces (6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al, \"Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(6):2536-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/34/41508/abstract-text/20525905/pubmed\" id=\"20525905\" target=\"_blank\">",
"        20525905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capponi VJ, Cox SR, Harrington EL, et al, \"Liquid Chromatographic Assay for Fluoxymesterone in Human Serum With Application to a Preliminary Bioavailability Study,\"",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1985, 74(3):308-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/34/41508/abstract-text/4009439/pubmed\" id=\"4009439\" target=\"_blank\">",
"        4009439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lenko HL, M&auml;enp&auml;&auml; J, and Perheentupa J, \"Acceleration of Delayed Growth With Fluoxymesterone,\"",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1982, 71(6):929-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/34/41508/abstract-text/7158332/pubmed\" id=\"7158332\" target=\"_blank\">",
"        7158332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stanhope R, Bommen M, and Brook CG, \"Constitutional Delay of Growth and Puberty in Boys: The Effect of a Short Course of Treatment With Fluoxymesterone,\"",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1985, 74(3):390-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/34/41508/abstract-text/4003064/pubmed\" id=\"4003064\" target=\"_blank\">",
"        4003064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strickland AL, \"Long-Term Results of Treatment With Low-Dose Fluoxymesterone in Constitutional Delay of Growth and Puberty and in Genetic Short Stature,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(4):716-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/34/41508/abstract-text/8464656/pubmed\" id=\"8464656\" target=\"_blank\">",
"        8464656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8466 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41508=[""].join("\n");
var outline_f40_34_41508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172838\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172817\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172818\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896230\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896231\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172797\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172840\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15863712\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172798\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172847\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172836\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172801\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172784\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299354\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172792\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386438\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172821\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355431\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5686408\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172794\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539862\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172783\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172800\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8466|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/61/18388?source=related_link\">",
"      Fluoxymesterone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/46/18147?source=related_link\">",
"      Fluoxymesterone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41509="Peritonsillar abscess with exudate";
var content_f40_34_41509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peritonsillar abscess with exudate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the bulging of the soft palate and increased tonsillar hypertrophy on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Diane Heatley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41509=[""].join("\n");
var outline_f40_34_41509=null;
var title_f40_34_41510="Management of lactotroph adenoma (prolactinoma) during pregnancy";
var content_f40_34_41510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of lactotroph adenoma (prolactinoma) during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41510/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/34/41510/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactotroph adenomas (prolactinomas) usually cause infertility because of the inhibitory effect of prolactin on gonadotropin secretion and sometimes because of the mass effect of a macroadenoma. However, our ability to treat both of these abnormalities allows most women with this disorder to become pregnant. Management during pregnancy is based on knowledge of the risks to the mother and the fetus.",
"   </p>",
"   <p>",
"    The management of women with lactotroph adenomas during pregnancy will be reviewed here. Other aspects of hyperprolactinemia and lactotroph adenomas are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131104\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103129573\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of women with lactotroph adenomas should begin before conception with advice to the woman and her partner about the risks of pregnancy to her (adenoma growth) and the fetus (exposure to dopamine agonists). Current data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    use during the first month of pregnancy (eg, ovulation induction) does not harm the fetus. Data for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    are reassuring as well. However, insufficient data are available about the use of either drug later in pregnancy. The main goals of treatment for women with lactotroph adenomas considering pregnancy include:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with microadenomas &ndash; Lower serum prolactin into the normal range to induce ovulation.",
"     </li>",
"     <li>",
"      Women with macroadenomas &ndash; Administer dopamine agonists or perform transsphenoidal surgery to decrease tumor size before attempting to conceive.",
"     </li>",
"     <li>",
"      During pregnancy, all women should be monitored for possible adenoma growth; growth that affects visual function should be treated with dopamine agonists or, if necessary, surgery (only in second trimester).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103130537\">",
"    <span class=\"h2\">",
"     Effect of pregnancy on tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal risk during pregnancy to a mother with a lactotroph adenoma is an increase in adenoma size sufficient to cause neurologic symptoms, most importantly visual impairment. The theoretical basis for an increase in size during pregnancy is that hyperestrogenemia causes lactotroph hyperplasia. As an example of the normal effect of estrogen, a study of 20 normal nonpregnant women and 32 normal pregnant women showed a progressive increase in pituitary size, as assessed by MR imaging, throughout pregnancy, so that the volume during the third trimester was more than double that in nonpregnant women (",
"    <a class=\"graphic graphic_figure graphicRef73519 \" href=\"mobipreview.htm?22/29/23005\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, in women with lactotroph adenomas who become pregnant, the hyperestrogenemia of pregnancy may increase the size of the adenoma.",
"   </p>",
"   <p>",
"    The risk that the increase in size of a lactotroph adenoma will be clinically important depends upon the size of the adenoma before pregnancy. For a microadenoma (tumor less than 10 mm in diameter) the risk is small. A review of 12 studies reporting a total of 658 patients with lactotroph microadenomas showed that only 2.7 percent exhibited a symptomatic increase in the size of the adenoma during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk is substantially higher in women with macroadenomas (tumors &ge;10 mm in diameter). In the same review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"     2",
"    </a>",
"    ], only 4.8 percent of 148 women who had macroadenomas that had been treated by prior surgery or radiation developed clinically significant enlargement during pregnancy, but 22.9 percent of 214 women who had not had such treatment did. Enlargement not accompanied by symptoms or visual field deficit was not counted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103129790\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103129798\">",
"    <span class=\"h2\">",
"     Before pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of women with lactotroph adenomas should begin before conception with advice to the woman and her partner about the potential risks of pregnancy to her and the fetus. The main concern for the mother is adenoma growth, while the potential risk for the fetus is exposure to dopamine agonists. (See",
"    <a class=\"local\" href=\"#H103129806\">",
"     'Ovulation induction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103130479\">",
"    <span class=\"h3\">",
"     Discuss risk of adenoma growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman who has a lactotroph microadenoma should be told that the risk of clinically important enlargement of her adenoma during pregnancy is very small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2-5\">",
"     2-5",
"    </a>",
"    ] and that it should not be a deterrent to becoming pregnant. (See",
"    <a class=\"local\" href=\"#H103130537\">",
"     'Effect of pregnancy on tumor size'",
"    </a>",
"    above.) She should also be told that in the unlikely event that symptoms due to growth of the adenoma do occur during pregnancy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    would likely be effective in reducing adenoma size. If she is willing to take this very low risk, she should be given bromocriptine or cabergoline",
"    <strong>",
"     before pregnancy",
"    </strong>",
"    in whatever dose is necessary to lower her serum prolactin concentration to normal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      can be used for this purpose. When the serum prolactin concentration is normal and menses have occurred regularly for a few months, the woman can attempt to become pregnant. Bromocriptine or cabergoline should be discontinued as soon as pregnancy has been confirmed, an approach that is safe given the lack of apparent toxicity during the first trimester [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H103129806\">",
"       'Ovulation induction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the adenoma is not responsive to a dopamine agonist, ovulation can usually be induced by administration of other ovulation induction agents, in particular,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link\">",
"       \"Overview of ovulation induction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10534154\">",
"    <span class=\"h3\">",
"     Macroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, women with lactotroph macroadenomas may develop clinically significant enlargement during pregnancy unless they receive pretreatment to remove or decrease the size of the adenoma. (See",
"    <a class=\"local\" href=\"#H103130537\">",
"     'Effect of pregnancy on tumor size'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103130740\">",
"    <span class=\"h4\">",
"     Dopamine agonists to decrease size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman with a lactotroph macroadenoma should be treated to shrink the adenoma before she attempts to become pregnant. She should be advised of the relatively higher risk of clinically important tumor enlargement during pregnancy, as described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H103130537\">",
"     'Effect of pregnancy on tumor size'",
"    </a>",
"    above.) Advice and monitoring depend upon how large the adenoma is. If the adenoma does not elevate the optic chiasm, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    for a sufficient period to shrink it substantially prior to trying to conceive. This should reduce the chance of clinically important enlargement during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Once this has occurred, the woman can attempt to become pregnant; the dopamine agonist should be discontinued when pregnancy has been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10534119\">",
"    <span class=\"h4\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the adenoma is very large or elevates the optic chiasm, pregnancy should be strongly",
"    <strong>",
"     discouraged",
"    </strong>",
"    until the adenoma has been treated by transsphenoidal surgery, and perhaps postoperatively by radiation. Postoperative treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    may also be helpful in reducing adenoma size further and lowering the serum prolactin concentration to normal. Such a regimen reduces the chance that symptomatic expansion will occur during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"     2",
"    </a>",
"    ], but it may still occur. Pregnancy should also be discouraged in a woman whose macroadenoma is unresponsive to bromocriptine and cabergoline, even if it is not elevating the optic chiasm, until the size has been greatly reduced by transsphenoidal surgery, because medical treatment would not likely be effective if the adenoma enlarges during pregnancy.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103129806\">",
"    <span class=\"h3\">",
"     Ovulation induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dopamine agonist is the treatment of choice for women with hyperprolactinemic anovulation. In women with a lactotroph adenoma, as an example, a marked reduction in the serum prolactin concentration occurs within two to three weeks (",
"    <a class=\"graphic graphic_figure graphicRef72539 \" href=\"mobipreview.htm?28/2/28717\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131441\">",
"    <span class=\"h4\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a dopamine agonist is needed to lower the serum prolactin concentration to permit ovulation, either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    is effective. Bromocriptine has the advantage of the greater certainty that it does not cause birth defects, but cabergoline has the advantage that it is more likely to be tolerated and more likely to be effective in lowering the prolactin. Of note, cabergoline also appears to be safe when used for infertility in women with hyperprolactinemic anovulation, but there are still fewer observed pregnancies with the drug when compared with bromocriptine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131526\">",
"    <span class=\"h5\">",
"     Bromocriptine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One potential risk to the fetus results from dopamine agonist treatment of hyperprolactinemia in order to permit ovulation and thereby conception. Although the treatment is customarily discontinued when pregnancy is confirmed, pregnancy has usually progressed at least two weeks before confirmation occurs and the drug discontinued, so the fetus is exposed to the dopamine agonist during that time. Rarely, dopamine agonist treatment is resumed during pregnancy if adenoma size increases so much as to impair vision.",
"   </p>",
"   <p>",
"    Data from over 6000 pregnancies are available to state that the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    during the first month of pregnancy does not harm the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"     2",
"    </a>",
"    ]; however, few data are available about the use of bromocriptine later in pregnancy. In this series, the incidence of spontaneous abortions (9.9 percent), multiple births (1.7 percent), and malformations (1.8 percent) were no higher than in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131533\">",
"    <span class=\"h5\">",
"     Cabergoline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from over 700 pregnancies in women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    at the time of conception suggest that this drug is safe as well. In this series, the incidence of spontaneous abortions (7.6 percent), multiple births (1.7 percent), and malformations (3.2 percent) were no higher than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2,8-14\">",
"     2,8-14",
"    </a>",
"    ]. Patients with Parkinson disease treated with high doses of cabergoline (eg, &gt;20 mg per week) have an increased risk of valvular heart disease, but this risk has not been demonstrated using the lower doses used for lactotroph adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1528?source=see_link&amp;anchor=H12#H12\">",
"     \"Valvular heart disease induced by drugs\", section on 'Hyperprolactinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available data, when a dopamine agonist is needed to lower the serum prolactin concentration to permit ovulation, we suggest describing what is known about",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    . Women who are especially concerned about the possibility of birth defects often choose bromocriptine and women who are more concerned about nausea from bromocriptine often choose cabergoline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131698\">",
"    <span class=\"h4\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The doses usually given are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , start with 1.25 mg at bedtime for one week, then 1.25 mg twice a day for one month. If the serum prolactin concentration does not fall to near-normal or normal by then, the dose can be increased to 2.5 mg twice a day and, if necessary, to 5.0 mg twice a day. If nausea occurs or if the prolactin does not respond, consider changing to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      , start at 0.25 twice a week. If the serum prolactin concentration is not normal after one to two months, the dose can be increased to 0.5 mg twice a week or, if necessary, 1.0 mg twice a week. Sometimes even much higher doses are needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of regular menstrual cycles during treatment indicates that the woman is ovulating. Following correction of hyperprolactinemia, approximately 80 percent of women will ovulate and pregnancy rates of 70 to 80 percent can be achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment should be stopped once pregnancy has been diagnosed because, as noted, the safety of continued usage has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103131690\">",
"    <span class=\"h2\">",
"     During pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with lactotroph adenomas, in particular, those with macroadenomas, should be monitored closely during pregnancy and while nursing. The approach outlined here is consistent with the 2011 Endocrine Society Clinical Practice Guidelines on the diagnosis and treatment of hyperprolactinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103130844\">",
"    <span class=\"h3\">",
"     Microadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the pregnancy, the woman should be seen every three months and asked about headaches and changes in vision. Most authorities recommend not measuring prolactin because serum prolactin can increase to as high as 400",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    during a normal pregnancy. The author&rsquo;s view is that in the setting of stable vision a value less than that is reassuring that the adenoma has not increased to a clinically significant degree. If no symptoms occur during pregnancy, serum prolactin can be measured two months after delivery or cessation of nursing, and if it is similar to the pretreatment value, the drug can be resumed. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Breastfeeding'",
"    </a>",
"    below.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Macroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with macroadenomas should also be seen at least every three months, and more often the larger the adenoma. A perceived change in vision should be assessed by a neuroophthalmologist. If before pregnancy the macroadenoma extends above the sella, visual fields should be done before pregnancy and every three months during the pregnancy, even if the patient has no visual symptoms. If a visual field defect consistent with a sellar mass is found, an MRI should be performed. If the adenoma has enlarged to a degree that could account for the defect, the woman should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    throughout the remainder of the pregnancy, and she should be seen at least once a month to re-evaluate symptoms and visual fields. This treatment will usually decrease the size of the adenoma and alleviate the symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If bromocriptine is used first, and the adenoma does not respond, cabergoline should then be administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/19\">",
"     19",
"    </a>",
"    ]. If cabergoline is not successful in alleviating severely compromised vision after several weeks, we suggest transsphenoidal surgery in the second trimester. In contrast, in the third trimester, surgery for persistent visual symptoms should be deferred until after delivery, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding does not increase the risk of lactotroph adenoma growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41510/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Therefore, breastfeeding is an option for women with micro- and macroadenomas that remained stable in size during pregnancy. However, dopamine agonist treatment should be withheld until breastfeeding is completed.",
"   </p>",
"   <p>",
"    In contrast, breastfeeding is contraindicated in women who have visual field impairment after delivery because they should be treated with a dopamine agonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25698?source=see_link\">",
"       \"Patient information: Prolactinoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/0/25603?source=see_link\">",
"       \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103130058\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of women with lactotroph adenomas should begin before conception with advice to the woman and her partner about the potential risks of pregnancy to her and the fetus. The main concern for the mother is adenoma growth, while the potential risk for the fetus is exposure to dopamine agonists.",
"     </li>",
"     <li>",
"      A woman who has a lactotroph microadenoma should be told that the risk of clinically important enlargement of her adenoma during pregnancy is very small and that it should not be a deterrent to becoming pregnant. (See",
"      <a class=\"local\" href=\"#H103130537\">",
"       'Effect of pregnancy on tumor size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective ovulation induction consists of lowering serum prolactin into the normal range with a dopamine agonist.",
"     </li>",
"     <li>",
"      When a dopamine agonist is needed to lower the serum prolactin concentration to permit ovulation, we suggest either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bromocriptine has the advantage of the greater certainty that it does not cause birth defects, but cabergoline has the advantage that it is more likely to be tolerated and more likely to be effective in lowering the prolactin. (See",
"      <a class=\"local\" href=\"#H103129806\">",
"       'Ovulation induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A woman who has a lactotroph macroadenoma should be advised of the relatively higher risk of clinically important adenoma enlargement during pregnancy and therefore the need for treatment to shrink the adenoma before attempting to become pregnant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with macroadenomas that do not elevate the optic chiasm, we suggest treatment with a dopamine agonist to decrease the size of the adenoma prior to pregnancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Once this has occurred, the woman can attempt to become pregnant; the dopamine agonist should be discontinued when pregnancy has been confirmed.",
"     </li>",
"     <li>",
"      For women with a macroadenoma that",
"      <strong>",
"       does",
"      </strong>",
"      elevate the optic chiasm, we suggest transsphenoidal surgery and then possibly radiation or dopamine agonist treatment before attempting to become pregnant. (See",
"      <a class=\"local\" href=\"#H10534154\">",
"       'Macroadenomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During pregnancy, women with either a micro- or macroadenoma should be seen every three months and asked about headaches and changes in vision. A perceived change in vision should be assessed by a neuroophthalmologist. A woman who has an adenoma that extends above the sella should have visual fields every three months, even if she does not notice a change in vision. An MRI should be performed if a visual field abnormality consistent with a pituitary adenoma is confirmed.",
"     </li>",
"     <li>",
"      If the MRI shows that the adenoma has enlarged to a degree that could account for the visual abnormality, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      throughout the remainder of the pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This treatment will usually decrease the size of the adenoma and alleviate the visual defect. If bromocriptine is used first, but the adenoma does not respond, we suggest a trial of cabergoline (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If cabergoline is not successful and vision is severely compromised, we suggest transsphenoidal surgery in the second trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the third trimester, surgery for persistent visual symptoms should be deferred until delivery if possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/1\">",
"      Gonzalez JG, Elizondo G, Saldivar D, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 1988; 85:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/2\">",
"      Molitch ME. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011; 25:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/3\">",
"      Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979; 31:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/4\">",
"      Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 1994; 121:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/5\">",
"      Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/6\">",
"      Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982; 247:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/7\">",
"      Ahmed M, al-Dossary E, Woodhouse NJ. Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies. Fertil Steril 1992; 58:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/8\">",
"      Schlechte JA. Update in pituitary 2010. J Clin Endocrinol Metab 2011; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/9\">",
"      Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/10\">",
"      Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/11\">",
"      Ono M, Miki N, Amano K, et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010; 95:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/12\">",
"      Colao A, Abs R, B&aacute;rcena DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008; 68:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/13\">",
"      Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 2010; 73:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/14\">",
"      Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/15\">",
"      Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/16\">",
"      Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986; 10:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/17\">",
"      Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983; 146:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/18\">",
"      van Roon E, van der Vijver JC, Gerretsen G, et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril 1981; 36:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/19\">",
"      Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/20\">",
"      Bronstein MD, Salgado LR, de Castro Musolino NR. Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 2002; 5:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41510/abstract/21\">",
"      Holmgren U, Bergstrand G, Hagenfeldt K, Werner S. Women with prolactinoma--effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh) 1986; 111:452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6629 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41510=[""].join("\n");
var outline_f40_34_41510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H103130058\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103131104\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103129573\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103130537\">",
"      Effect of pregnancy on tumor size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103129790\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103129798\">",
"      Before pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103130479\">",
"      - Discuss risk of adenoma growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10534154\">",
"      - Macroadenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103130740\">",
"      Dopamine agonists to decrease size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10534119\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103129806\">",
"      - Ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103131441\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H103131526\">",
"      - Bromocriptine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H103131533\">",
"      - Cabergoline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103131698\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103131690\">",
"      During pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103130844\">",
"      - Microadenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Macroadenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103130058\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6629|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/29/23005\" title=\"figure 1\">",
"      Pregnancy and pituitary size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/2/28717\" title=\"figure 2\">",
"      Dopamine agonists in prolactinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1528?source=related_link\">",
"      Valvular heart disease induced by drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41511="Anaerobic bacteria: History and role in normal human flora";
var content_f40_34_41511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anaerobic bacteria: History and role in normal human flora",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41511/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/34/41511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria are the predominant forms of life in the human body. While the role of these microbes as pathogens was well established at the turn of the 20th century, they are often neglected in part due to the fact that few clinical laboratories ever detect them. Important features that may limit detection of some of these organisms are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The lack of widely available diagnostic methods other than Gram stain and culture",
"     </li>",
"     <li>",
"      Fastidious growth requirements that often limit recovery",
"     </li>",
"     <li>",
"      Ubiquity on mucocutaneous surfaces that hampers obtaining meaningful cultures",
"     </li>",
"     <li>",
"      The presence of mixed flora including other known pathogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the past several decades, there has been renewed interest in anaerobic infections, based upon verification of their role as pathogens by recovery from infected sites, efficacy of antibiotic treatment, and elucidation of virulence factors. We now appear to be in an era where therapy is frequently directed at anaerobes based upon an assumption that the organisms are there and that specific antibiotics are effective.",
"   </p>",
"   <p>",
"    The history of the appreciation of anaerobes as pathogens and the composition of normal flora in humans will be reviewed here. The pathophysiology, clinical clues, recovery, and range of infections caused by these organisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34424?source=see_link\">",
"     \"Pathophysiology; clinical clues and recovery of organisms in anaerobic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF ANAEROBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria are defined as bacteria that grow in the absence of oxygen and fail to show surface growth in 10 percent carbon dioxide in air. They may be further classified by relative aerotolerance: strict anaerobes cannot tolerate 0.5 percent oxygen; most clinically important anaerobes (Bacteroides fragilis, Prevotella melaninogenica [formerly classified as Bacteroides melaninogenicus], and Fusobacterium nucleatum) are moderate anaerobes that tolerate 2 to 8 percent oxygen. Most of these organisms can survive in air for sustained periods, but they cannot replicate in atmospheric oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Louis Pasteur is credited with the discovery of anaerobes with the successful cultivation of Clostridium butyricum in the absence of atmospheric oxygen in 1862 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/1\">",
"     1",
"    </a>",
"    ]. Veillon and Zuber from the Faculty of Medicine of Paris published a series of important contributions in the 1890s concerning the role of anaerobic bacteria as the cause of putrid discharge from infections at multiple anatomic sites, including pelvic infections, brain abscess, lung gangrene, and appendicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early reports",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic toxin-mediated clostridial syndromes, botulism and tetanus, were also well recognized by the end of the nineteenth century. In fact, Clostridium tetani was recovered in pure culture by 1890, and studies of tetanus immunization had begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the beginning of the twentieth century, numerous papers in the French and German literature reviewed the role of anaerobic bacteria in diverse types of infections. Many were described as \"fusospirochetal infections,\" characterized by the appearance of fusiform gram-negative rods (presumably F. nucleatum) and anaerobic spirochetes. In retrospect, it seems that these infections were probably analogous to those encountered in current practice, but the organisms identified generated considerable interest owing to their unique morphologic character.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the major contributions was the observation by Schottmueller that anaerobic streptococci, rather than group A beta-hemolytic streptococci, were actually the predominant pathogens in puerperal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/3\">",
"     3",
"    </a>",
"    ]. He postulated that the infection was acquired endogenously from the normal genital flora. This was a novel thesis at the time because nearly all infectious diseases were thought to be exogenous and contagious.",
"   </p>",
"   <p>",
"    Contributions by American investigators in the early 1900s included the hallmark studies of the bacteriology and pathophysiology of lung abscess by David Smith in the late 1920s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This investigator noted that the organisms in the abscess walls obtained at autopsy resembled those seen in the gingival crevice, leading to the postulate that aspiration of gingival crevice bacteria was the mechanism of infection. This hypothesis was subsequently supported by the intratracheal inoculation of pyorrhea pus into experimental animals to demonstrate the sequential progression from pneumonitis (\"aspiration pneumonia\") to lung abscess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=see_link\">",
"     \"Lung abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an amazing series of experiments, 17 different organisms were isolated from the inoculum and then each used alone and in combination with intratracheal challenge to various animals. Eventually, he showed that four microbial species were required to reproduce lung abscess: anaerobic streptococci, an anaerobic spirochete, an anaerobic vibrio, and an anaerobic fusiform bacillus. This was one of the first studies of microbial synergy, the demonstration that two or more organisms could produce a pathologic lesion that could not be reproduced with a simpler inoculum.",
"   </p>",
"   <p>",
"    Two American surgeons, Meleney and Altemeier, made additional important contributions. Meleney noted the role of anaerobic bacteria in soft tissue infections and described the condition subsequently known as \"Meleney synergistic gangrene,\" a rare but characteristic eroding ulcer at the site of retention sutures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .) This lesion harbors Staphylococcus aureus and an anaerobic streptococcus and can be reproduced in animals only with an inoculum of both.",
"   </p>",
"   <p>",
"    Altemeier examined the bacteriology of appendicitis in the late 1930s and was able to isolate anaerobic bacteria from 96 of 100 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/6\">",
"     6",
"    </a>",
"    ]. He also noted that putrid discharge was found exclusively in the presence of infections involving anaerobic bacteria and that these were also the only organisms to produce the characteristic odor both in vivo and in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Two decades of disinterest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in anaerobic infections largely disappeared in the period from 1940 through 1960. There were relatively few clinical reports, and clinical laboratories made no attempt to recover anaerobes. The organisms seemed to be out of sight and out of mind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renewed attention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renewed interest in anaerobic infections in the middle and late 1960s followed three simultaneous developments.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GasPak jar, which made isolation of anaerobes relatively easy for most microbiology laboratories, became available.",
"     </li>",
"     <li>",
"      The taxonomic classification of anaerobic bacteria was finally put in order, primarily by the tedious studies by workers from the Virginia Polytechnic Institute.",
"     </li>",
"     <li>",
"      Studies of the activity of antibiotics against anaerobes in vitro and in clinical trials were conducted by Sydney Finegold and others; this work initially highlighted the potential role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/24/43396?source=see_link\">",
"       lincomycin",
"      </a>",
"      , and subsequent reports dealt with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      , and a host of other antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies from 1970 through 1980 showed that anaerobic bacteria accounted for a relatively large number of infections, although the frequency was profoundly influenced by the anatomic site and the mechanism of disease acquisition (exogenous versus endogenous). Detection of anaerobes in the laboratory was also highly variable depending upon the methods used to collect, transport, and process specimens. A review of the experience at the Mayo Clinic in the early 1970s found that B. fragilis was second only to Escherichia coli as a cause of gram-negative bacillary bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/9\">",
"     9",
"    </a>",
"    ]. There were multiple additional studies from the 1970s (summarized below) that showed high yields of anaerobes when properly studied. These results have been translated into practice through the widespread use of drugs directed specifically at anaerobic bacteria; two of the most frequent are:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The extensive publicity accorded to anaerobic bacteria and anaerobic infections in the 1970s resulted in general acceptance of these organisms as major pathogens in selected types of infections. This recognition was accompanied by large, multicenter clinical trials, studies of antibiotic sensitivity testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], and the widespread use of antimicrobials with coverage against anaerobes.",
"   </p>",
"   <p>",
"    The incidence of anaerobic infections was reduced by one of the most successful education campaigns in the history of modern medicine. The result was a virtual disappearance of anaerobic bacterial bacteremia to the extent that some authorities proposed a discontinuation of routine anaerobic blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, a subsequent increase in both anaerobic infections and anaerobes with resistance to commonly used antibiotics has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Current status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"anaerobic bandwagon\" of the 1970s appeared to be highly effective in achieving recognition of anaerobic bacteria and their role in selected infections. This resulted in increased availability of anaerobic microbiology and appropriate use of antibiotics.",
"   </p>",
"   <p>",
"    However, there is concern that some anaerobic infections are not being detected due in part to a decline in the quality of microbiology laboratories, reflecting economic realities, outsourcing, and reliance on empiric antibiotics. In addition, the incidence of anaerobic infections appears to be rising, which is likely the result of an increase in the number of patients with complex underlying illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, one report from the Mayo Clinic found a decline in the incidence of anaerobic bacteremia from 1974 to 1988, followed by an increase to an average of 53 cases per year from 1993 to 1996 and to 94 cases per year from 2001 to 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/16\">",
"     16",
"    </a>",
"    ]. This issue is increasingly relevant in the context of both recognition and antibiotic selection due to increasing resistance of anaerobes to antibiotics, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , carbapenems, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaerobic bacterial infections\", section on 'Antibiotic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NORMAL FLORA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mucocutaneous surfaces of humans harbor a rich indigenous flora composed of aerobic and anaerobic bacteria, the microbial species and concentrations of which vary at different anatomic sites (",
"    <a class=\"graphic graphic_table graphicRef78878 \" href=\"mobipreview.htm?30/3/30780\">",
"     table 1",
"    </a>",
"    ). Anaerobic bacteria are the dominant forms, often accounting for 99 to 99.9 percent of the culturable flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. The total number of bacterial species in a single individual probably exceeds 500.",
"   </p>",
"   <p>",
"    However, most of the normal flora cannot be grown or characterized by current laboratory methods. This was illustrated in an analysis of 13,555 prokaryotic ribosomal RNA gene sequences from the colon in which most bacteria were considered uncultivated and novel microorganisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Upper airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper airways, including the oral cavity, nasal passages, oropharynx, and nasopharynx, harbor a complex flora that differs at various sites despite anatomic continuity; these are known as ecologic niches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/17\">",
"     17",
"    </a>",
"    ]. Concentrations of bacteria in saliva are approximately",
"    <span class=\"nowrap\">",
"     10(8)/mL",
"    </span>",
"    with 90 percent anaerobic bacteria; the predominant organism is Veillonella parvula. Dental plaque includes a complicated matrix of bacteria, including Streptococcus mutans, the principal organism implicated in dental caries, but anaerobic bacteria have also been implicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The environment in the gingival crevice is similar to that of the colon in that the oxidation-reduction potential is -300 mV, concentrations of bacteria reach",
"    <span class=\"nowrap\">",
"     10(12)/mL",
"    </span>",
"    (the geometric limits with which bacteria may occupy space), and anaerobic bacteria account for 99 percent of the culturable flora. In healthy persons, the sinuses, eustachian tubes, and respiratory passages below the level of the larynx are generally sterile.",
"   </p>",
"   <p>",
"    The most important anaerobic potential pathogens found in the upper airways are Fusobacterium nucleatum, Prevotella melaninogenica, the Prevotella oralis group, the Bacteroides ureolyticus group, and Peptostreptococcus spp, which represent the predominant organisms in anaerobic oral and pleuropulmonary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal (GI) tract shows marked variations in bacteriologic patterns in concentrations at different levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is protected by the gastric acid barrier and consequently harbors relatively small numbers of bacteria derived from swallowed salivary bacteria that are predominately gram-positive. The number and types of bacteria increase with loss of gastric acidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small bowel is the site of rapid motility so the organisms commonly found are simply passing through. Interruption of this flow, as with a stagnant segment (stricture, obstruction, diverticulum, blind loop), results in colonic concentrations of bacteria with a predominance of anaerobes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. This bacterial overgrowth pattern may be responsible for malabsorption and is best treated with antibiotics directed against anaerobes. There is speculation that overgrowth may play a role in irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12697?source=see_link&amp;anchor=H19618505#H19618505\">",
"     \"Pathophysiology of irritable bowel syndrome\", section on 'Alteration in fecal microflora'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest concentrations of anaerobic bacteria are found in the relatively stagnant terminal ileum and colon, where concentrations reach 10(11) per gram, and anaerobic bacteria account for approximately 99.9 percent of the cultivable flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The most important and frequent anaerobic bacteria are Bacteroides spp (principally members of the B. fragilis group), Prevotella spp, Clostridium spp, and Peptostreptococcus spp. It should be noted that most of the bacteria in the human colon cannot be cultivated. This has been studied by analysis of 16S rRNA gene sequences, which show substantial individual variation that appears strongly influenced by host phylogeny and diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/18,28,29\">",
"     18,28,29",
"    </a>",
"    ]. The totality is referred to as &ldquo;the gut microbiome.&rdquo; Studies in animals suggest a possible role for this microbiome in important conditions, such as obesity and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The colon flora becomes established after weaning and is thought to remain relatively stable throughout life unless it is disrupted by antibiotic treatment. Its role in maintaining health is believed to be in establishing ecologic balance by preventing colonization with exogenous organisms.",
"   </p>",
"   <p>",
"    This protection, known as \"colonization resistance,\" is compromised with antibiotic treatment, which enhances the potential for infection with enteric pathogens and colonization by resistant bacteria, such as vancomycin-resistant enterococci (VRE), and resistant gram-negative bacilli. These bacteria cause many nosocomial infections, including serious infections in patients with neutropenia or critical illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34840?source=see_link\">",
"     \"Infections and antimicrobial resistance in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A logical extension of this thesis is \"selective modulation of the fecal flora\" by use of antibiotics that are directed against aerobic gram-negative bacilli but preserve the anaerobic component of the flora in an effort to prevent colonization by resistant strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/31\">",
"     31",
"    </a>",
"    ]. The goal is to prevent nosocomial pneumonia, bacteremia, and other serious infections in patients who are critically ill. The majority of data come from studies of selective decontamination of the colonic flora to prevent nosocomial or ventilator-associated pneumonia. These studies generally show a highly significant reduction in rates of nosocomial pneumonia, but no reduction in mortality rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Selective decontamination of the digestive tract'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another important role of colonic bacteria is defense against two forms of antibiotic-associated diarrhea: The most familiar form is C. difficile-associated diarrhea or colitis which is a toxin-mediated, potentially life-threatening disease that presumably results when C. difficile spores in the colon transform to vegetative forms with toxin production due to antibiotic elimination of critical components of the competing colonic flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/32\">",
"     32",
"    </a>",
"    ]. The second form of antibiotic-associated diarrhea appears to be due to elimination of colonic anaerobes which are critical for metabolizing carbohydrates to produce short chain fatty acids that are absorbed in the colon; with elimination of critical anaerobes (especially Clostridia species, Bacteroides and Bifidobacteria) the colon cannot handle the carbohydrates and the result is an osmotic diarrhea that promptly resolves when antibiotics are stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genital tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flora of the female genital tract is less stable than that of the GI tract. Concentrations of bacteria in the vagina or cervix average approximately 10(8) per mL during reproductive years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], but there is considerable variation [10(5) to 10(11) per mL] in studies that may be related to technique or to real differences. Simultaneous cultures of material from the cervix and vagina show unique bacteriologic patterns, and sequential cultures show considerable shifts at various stages of the menstrual cycle that may be hormonally influenced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Approximately, 50 percent are anaerobic bacteria, but this can vary. In fact, approximately 20 percent of women have no detectable anaerobes or at least low concentrations.",
"   </p>",
"   <p>",
"    The dominant organisms are aerobic, microaerobic, and anaerobic lactobacilli; the most common anaerobes are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    , Peptostreptococcus, and Bacteroides spp, including Prevotella bivia (formerly Bacteroides bivius). B. fragilis is found in only 2 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/38\">",
"     38",
"    </a>",
"    ]. Factors that appear to influence the bacteriologic findings in the genital tract include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Menarche",
"     </li>",
"     <li>",
"      Menopause",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Antibiotic therapy",
"     </li>",
"     <li>",
"      Gynecologic surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of the genital tract flora in maintaining homeostasis is not well studied, although antibiotic treatment clearly predisposes to vaginal candidiasis. Bacterial vaginosis (BV) appears to reflect dysbiosis of the genital tract flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/35,43\">",
"     35,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concentrations of lactobacilli, which presumably maintain homeostasis, are notably reduced.",
"     </li>",
"     <li>",
"      The dominant organisms are anaerobic bacteria as indicated by Gram stain and culture.",
"     </li>",
"     <li>",
"      Vaginal effluent contains a predominance of the short chain volatile fatty acids produced by anaerobes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current therapeutic recommendations for BV are restricted to drugs directed against anaerobes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link\">",
"     \"Bacterial vaginosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin flora contains large numbers of anaerobic bacteria. The predominant organisms are Propionibacterium acnes and, to a lesser extent, other species of Propionibacterium and Peptostreptococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41511/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaerobic bacteria are the predominant forms of life in the human body. While the role of these microbes as pathogens was well established at the turn of the 20th century, they are often neglected in part due to the fact that few clinical laboratories reliably detect them. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the past several decades, there has been renewed interest in anaerobic infections, based upon verification of their role as pathogens by recovery from infected sites, efficacy of antibiotic treatment, and elucidation of virulence factors. We now appear to be in an era where therapy is frequently directed at anaerobes based upon an assumption that the organisms are there and that specific antibiotics are effective. &nbsp;(See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaerobic bacteria are defined as bacteria that grow in the absence of oxygen and fail to show surface growth in 10 percent carbon dioxide in air. They may be further classified by relative aerotolerance: strict anaerobes cannot tolerate 0.5 percent oxygen; most clinically important anaerobes (Bacteroides fragilis, Prevotella melaninogenica [formerly classified as Bacteroides melaninogenicus], and Fusobacterium nucleatum) are moderate anaerobes that tolerate 2 to 8 percent oxygen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of anaerobes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is concern that some anaerobic infections are not being detected due in part to a decline in the appropriate testing in microbiology laboratories, reflecting economic realities, outsourcing, and reliance on empiric antibiotics. In addition, the incidence of anaerobic infections appears to be rising, which is likely the result of an increase in the number of patients with complex underlying illnesses. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Current status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most mucocutaneous surfaces of humans harbor a rich indigenous flora composed of aerobic and anaerobic bacteria, the microbial species and concentrations of which vary at different anatomic sites (",
"      <a class=\"graphic graphic_table graphicRef78878 \" href=\"mobipreview.htm?30/3/30780\">",
"       table 1",
"      </a>",
"      ). Anaerobic bacteria are the dominant forms, often accounting for 99 to 99.9 percent of the culturable flora. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normal flora'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The upper airways, including the oral cavity, nasal passages, oropharynx, and nasopharynx, harbor a complex flora that differs at various sites despite anatomic continuity. The most important potential anaerobic pathogens found in the upper airways are Fusobacterium nucleatum, Prevotella melaninogenica, the Prevotella oralis group, the Bacteroides ureolyticus group, and Peptostreptococcus spp, which represent the predominant organisms in anaerobic oral and pleuropulmonary infections. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Upper airways'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gastrointestinal (GI) tract shows marked variations in bacteriologic patterns in concentrations at different levels. The stomach is protected by the gastric acid barrier and consequently harbors relatively small numbers of bacteria derived from swallowed salivary bacteria that are predominately gram-positive. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Normal flora'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Stomach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The small bowel is the site of rapid motility so the organisms commonly found are simply passing through. Interruption of this flow, as with a stagnant segment (stricture, obstruction, diverticulum, blind loop), results in colonic concentrations of bacteria with a predominance of anaerobes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Small intestine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The largest concentrations of anaerobic bacteria are found in the relatively stagnant terminal ileum and colon, where concentrations reach 10(11) per gram, and anaerobic bacteria account for approximately 99.9 percent of culturable flora. The most important and frequent anaerobic bacteria are Bacteroides spp (principally members of the B. fragilis group), Prevotella spp, Clostridium spp, and Peptostreptococcus spp. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Colon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dominant organisms in the female genital tract are aerobic, microaerobic, and anaerobic lactobacilli; the most common anaerobes are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      , Peptostreptococcus, and Bacteroides spp, including Prevotella bivia (formerly Bacteroides bivius). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Genital tract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skin flora contains large numbers of anaerobic bacteria. The predominant organisms are Propionibacterium acnes and, to a lesser extent, other species of Propionibacterium and Peptostreptococcus. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/1\">",
"      Finegold SM, George WL, Mulligan ME. Anaerobic infections. Part II. Dis Mon 1985; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/2\">",
"      Veillon, A, Zuber, A. Sur quelques microbes strictment anaerobies et leur role clans la pathologie humaine. C R Soc Biol (Paris) 1897; 49:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/3\">",
"      Schottmueller, H. Allgemeinen krankenhaus hamburg-eppendorf. Mitt Grenzt Med Chir 1910; 21:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/4\">",
"      Smith, DT. Fusospirochetal disease of the lungs, its bacteriology, pathology and experimental reproduction. Am Rev Tuberc 1927; 16:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/5\">",
"      Smith, DT. Fusospirochetal disease of the lungs produced with cultures from Vincent's angina. J Infect Dis 1930; 46:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/6\">",
"      Altemeier WA. THE BACTERIAL FLORA OF ACUTE PERFORATED APPENDICITIS WITH PERITONITIS: A BACTERIOLOGIC STUDY BASED UPON ONE HUNDRED CASES. Ann Surg 1938; 107:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/7\">",
"      Altemeier, WA. The cause of the putrid odor of perforated appendicitis with peritonitis. Ann Surg 1938; 107:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/8\">",
"      Gorbach SL, Bartlett JG. Anaerobic infections. 1. N Engl J Med 1974; 290:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/9\">",
"      Wilson WR, Martin WJ, Wilkowske CJ, Washington JA 2nd. Anaerobic bacteremia. Mayo Clin Proc 1972; 47:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/10\">",
"      Cornick NA, Cuchural GJ Jr, Snydman DR, et al. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother 1990; 25:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/11\">",
"      Finegold SM. Clinical relevance of antimicrobial susceptibility testing. Eur J Clin Microbiol Infect Dis 1992; 11:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/12\">",
"      Tally FP, Cuchural GJ, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother 1983; 23:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/13\">",
"      Chandler MT, Morton ES, Byrd RP Jr, et al. Reevaluation of anaerobic blood cultures in a Veteran population. South Med J 2000; 93:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/14\">",
"      James PA, al-Shafi KM. Clinical value of anaerobic blood culture: a retrospective analysis of positive patient episodes. J Clin Pathol 2000; 53:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/15\">",
"      Iwata K, Takahashi M. Is anaerobic blood culture necessary? If so, who needs it? Am J Med Sci 2008; 336:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/16\">",
"      Lassmann B, Gustafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007; 44:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/17\">",
"      Sutter VL. Anaerobes as normal oral flora. Rev Infect Dis 1984; 6 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/18\">",
"      Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/19\">",
"      Kuriyama T, Williams DW, Yanagisawa M, et al. Antimicrobial susceptibility of 800 anaerobic isolates from patients with dentoalveolar infection to 13 oral antibiotics. Oral Microbiol Immunol 2007; 22:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/20\">",
"      Ishida T, Hashimoto T, Arita M, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med 2001; 40:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/21\">",
"      Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993; 16 Suppl 4:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/22\">",
"      Broido PW, Gorbach SL, Condon RE, Nyhus LM. Upper intestinal microfloral control. Effects of gastric acid and vagal denervation on bacterial concentrations. Arch Surg 1973; 106:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/23\">",
"      Finegold SM, Attebery HR, Sutter VL. Effect of diet on human fecal flora: comparison of Japanese and American diets. Am J Clin Nutr 1974; 27:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/24\">",
"      Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974; 27:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/25\">",
"      Mackowiak PA. The normal microbial flora. N Engl J Med 1982; 307:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/26\">",
"      Othman M, Ag&uuml;ero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol 2008; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/27\">",
"      Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/28\">",
"      Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/29\">",
"      Ley RE, Hamady M, Lozupone C, et al. Evolution of mammals and their gut microbes. Science 2008; 320:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/30\">",
"      Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010; 44 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/31\">",
"      van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982; 10:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/32\">",
"      Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/33\">",
"      Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004; 42:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/34\">",
"      Bartlett, JG, Polk, BF. Bacterial flora of the vagina: quantitative study. Rev Infect Dis 1984; 6:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/35\">",
"      Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/36\">",
"      Hillier SL, Krohn MA, Klebanoff SJ, Eschenbach DA. The relationship of hydrogen peroxide-producing lactobacilli to bacterial vaginosis and genital microflora in pregnant women. Obstet Gynecol 1992; 79:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/37\">",
"      Sautter RL, Brown WJ. Sequential vaginal cultures from normal young women. J Clin Microbiol 1980; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/38\">",
"      Hammerschlag MR, Alpert S, Rosner I, et al. Microbiology of the vagina in children: normal and potentially pathogenic organisms. Pediatrics 1978; 62:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/39\">",
"      Goplerud CP, Ohm MJ, Galask RP. Aerobic and anaerobic flora of the cervix during pregnancy and the puerperium. Am J Obstet Gynecol 1976; 126:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/40\">",
"      Ohm MJ, Galask RP. Bacterial flora of the cervix from 100 prehysterectomy patients. Am J Obstet Gynecol 1975; 122:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/41\">",
"      Ohm MJ, Galask RP. The effect of antibiotic prophylaxis on patients undergoing vaginal operations. II. Alterations of microbial flora. Am J Obstet Gynecol 1975; 123:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/42\">",
"      Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev 1991; 4:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41511/abstract/43\">",
"      Nielsen ML, Raahave D, Stage JG, Justesen T. Anaerobic and aerobic skin bacteria before and after skin-disinfection with chlorhexidine: an experimental study in volunteers. J Clin Pathol 1975; 28:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5522 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41511=[""].join("\n");
var outline_f40_34_41511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF ANAEROBES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early reports",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Two decades of disinterest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renewed attention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Current status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NORMAL FLORA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Upper airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Stomach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Small intestine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genital tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5522|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/3/30780\" title=\"table 1\">",
"      Bacteriology normal human flora",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/1/34840?source=related_link\">",
"      Infections and antimicrobial resistance in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34424?source=related_link\">",
"      Pathophysiology; clinical clues and recovery of organisms in anaerobic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41512="Viral exanthem";
var content_f40_34_41512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58169%7EDERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58169%7EDERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Viral exanthem",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules are present on the skin of this patient with a viral exanthem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar lentigines presenting as brown macules on the dorsum of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown macules are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41512=[""].join("\n");
var outline_f40_34_41512=null;
var title_f40_34_41513="Diagnosis and treatment of intestinal ischemia I";
var content_f40_34_41513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62760%7EGAST%2F76406%7EGAST%2F55391%7EGAST%2F65146%7EGAST%2F76899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62760%7EGAST%2F76406%7EGAST%2F55391%7EGAST%2F65146%7EGAST%2F76899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 607px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 740px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 622px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia IV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 663px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 572px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41513=[""].join("\n");
var outline_f40_34_41513=null;
var title_f40_34_41514="Pathology and prognostic determinants of colorectal cancer";
var content_f40_34_41514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology and prognostic determinants of colorectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Carolyn C Compton, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/34/41514/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/34/41514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a common and lethal disease. Approximately 142,820 new cases are diagnosed each year in the United States, of which 102,480 are colon and the remainder rectal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/1\">",
"     1",
"    </a>",
"    ]. Annually, approximately 50,830 Americans die of CRC, accounting for approximately 9 percent of all cancer deaths. Global, country-specific data on incidence and mortality are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Surgical resection is the primary treatment modality for early stage CRC (stage I through III) (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ), and the most powerful tool for assessing prognosis following potentially curative surgery is pathologic analysis of the resected specimen. Although the parameters that determine pathologic stage are the strongest predictors of postoperative outcome, other clinical, molecular, and histologic features may influence prognosis independent of stage. Among patients with stage IV disease, prognosis is more closely tied to the location and extent of distant metastatic disease.",
"   </p>",
"   <p>",
"    Here we will discuss the pathology of CRC and the determinants of prognosis following surgical resection, with particular attention to the strength of the evidence supporting each factor. The molecular pathogenesis of CRC, clinical presentation, and staging evaluation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gross appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all CRCs originate in adenomas or flat dysplasia, they evolve into different morphologic patterns with invasion and expansion. Tumors in the proximal or right colon usually appear grossly as polypoid or fungating exophytic masses. Occult bleeding may result in the clinical presentation of an unexplained iron deficiency anemia.",
"   </p>",
"   <p>",
"    In contrast, tumors involving the distal or left colon are more commonly annular or encircling lesions that produce an \"apple-core\" or \"napkin-ring\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82202 graphicRef75818 \" href=\"mobipreview.htm?35/18/36128\">",
"     image 1A-B",
"    </a>",
"    ). The bowel lumen becomes constricted and narrowed, producing symptoms of bowel dysfunction (eg, constipation, diarrhea, or bowel obstruction). The presence of clinical bowel obstruction or perforation of the bowel wall worsens the prognosis overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synchronous colon cancers, defined as two or more distinct primary tumors separated by normal bowel and not due to direct extension or metastasis, occur in 3 to 5 percent of patients with CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The incidence is closer to 2.5 percent when patients with hereditary nonpolyposis colorectal cancer (HNPCC) are excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/7\">",
"     7",
"    </a>",
"    ]. Synchronous primaries have the same prognosis as a solitary cancer when the highest stage of disease at presentation is compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite differences in their gross appearance, right and left sided colon cancers are microscopically similar, and they have a similar prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histologic type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of CRCs are adenocarcinomas, which are further classified by histologic grade. Other histologic types are relatively unusual (",
"    <a class=\"graphic graphic_table graphicRef68703 \" href=\"mobipreview.htm?9/50/10027\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although a number of proposed grading schemas for CRC appear in the literature, none is widely accepted or employed. In general, the histologic grade of differentiation predominantly takes into account the degree to which there are well-formed glands; the inclusion of cytologic or other features in the estimation of grade is variable.",
"   </p>",
"   <p>",
"    Gland formation is present to greater or lesser degrees in well differentiated and moderately differentiated tumors (low-grade tumors when using a two-tiered grading system), respectively. In contrast, poorly differentiated or undifferentiated adenocarcinomas (high-grade tumors) do not form well-defined glandular structures, consisting predominantly of solid sheets or cords of infiltrating cells, often with marked cellular atypia, pleomorphism, and a high mitotic rate. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Tumor grade'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many tumors produce mucin, which may remain within the cells or be secreted. Extracellular mucin dissects through the tumor wall, aiding its local extension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/9\">",
"     9",
"    </a>",
"    ]. Tumors producing copious amounts of extracellular mucin (ie, mucin comprising &ge;50 percent of the tumor mass) are classified as mucinous carcinomas (",
"    <a class=\"graphic graphic_table graphicRef68703 \" href=\"mobipreview.htm?9/50/10027\">",
"     table 2",
"    </a>",
"    ). This histologic type accounts for approximately 11 to 17 percent of all CRCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Mucinous carcinomas have a predilection for the rectum and sigmoid colon, they tend to present at a more advanced stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/13\">",
"     13",
"    </a>",
"    ], and they may have a poor responsiveness to upfront (neoadjuvant) chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/14\">",
"     14",
"    </a>",
"    ] and fluoropyrimidine-based chemotherapy, although this is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530415#H589530415\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Molecular prognostic and predictive factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some non-gland forming carcinomas, intracellular mucin may be a dominant feature that displaces tumor cell nuclei to the side. When &ge;50 percent of the tumor is made up of cells of this type, it is classified as a signet ring cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef67584 \" href=\"mobipreview.htm?10/0/10249\">",
"     picture 1",
"    </a>",
"    ). They account for only 1 to 2 percent of all CRCs, but signet ring carcinomas are aggressive variants, with a propensity for extensive intramural spread and peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/9,15,16\">",
"     9,15,16",
"    </a>",
"    ]. In one report of 1600 consecutive patients with CRC, 14 had signet ring carcinomas; of whom 93 percent had stage III or IV disease at diagnosis and 64 percent had peritoneal spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some cancers, particularly those arising in the distal colon, contain areas of squamous differentiation and are termed adenosquamous carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/17\">",
"     17",
"    </a>",
"    ]. These rare tumors account for between 0.05 and 0.2 percent of all colorectal malignancies and are associated with higher overall and colorectal-specific mortality as compared to adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10 percent of CRCs, particularly poorly differentiated tumors, contain foci of neuroendocrine differentiation. Non-gland forming tumors with extensive neuroendocrine differentiation, classified as small cell carcinomas, have a poorer prognosis. However, the prognostic importance of focal neuroendocrine differentiation within other histologic types is unclear. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Focal neuroendocrine differentiation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link\">",
"     \"Extrapulmonary small cell cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The medullary carcinoma subtype, the most recent addition to the WHO classification of CRC (",
"    <a class=\"graphic graphic_table graphicRef68703 \" href=\"mobipreview.htm?9/50/10027\">",
"     table 2",
"    </a>",
"    ), is a distinctive type of non-gland forming cancer composed of large eosinophilic, polygonal cells that grow in solid sheets and are heavily infiltrated by small lymphocytes (ie, tumor infiltrating lymphocytes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/20\">",
"     20",
"    </a>",
"    ]. The importance of recognizing this tumor type and differentiating it from undifferentiated carcinoma is its association with microsatellite instability and the HNPCC syndrome (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Category IIB factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Appendix cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the vermiform appendix is rare. Primary malignant tumors of the appendix are found in 0.1 percent of all appendectomy specimens; the majority are carcinoids, but approximately one-third are adenocarcinomas. Significantly, metachronous or synchronous primary neoplasms, particularly involving the gastrointestinal (GI) tract, are common in patients with appendiceal tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H8#H8\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Epithelial tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appendiceal adenocarcinomas commonly spread intraperitoneally. When these carcinomas are mucin secreting (mucinous cystadenocarcinomas) and present with peritoneal dissemination, they produce the clinical picture of a pseudomyxoma peritonei. The histologic spectrum of tumors that are associated with this clinical pattern ranges from mucinous cystadenomas to the adenocarcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary mucinous epithelial ovarian carcinoma only rarely presents similarly, but may be considered in the differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunohistochemistry (IHC) can help with the distinction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Carcinomas of colorectal origin (including the appendix) are almost always cytokeratin (CK) 20 positive and CK 7 negative, whereas ovarian carcinomas have different staining characteristics (",
"    <a class=\"graphic graphic_table graphicRef58475 \" href=\"mobipreview.htm?20/45/21212\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The natural history and prognosis of appendiceal adenocarcinomas differ from that of adenocarcinomas arising in other large bowel sites (",
"    <a class=\"graphic graphic_table graphicRef74667 \" href=\"mobipreview.htm?25/8/25739\">",
"     table 4",
"    </a>",
"    ). As a result, the most recent 2010 edition of the AJCC (American Joint Committee on Cancer) cancer staging manual contains a separate staging classification for these tumors (",
"    <a class=\"graphic graphic_table graphicRef70538 \" href=\"mobipreview.htm?17/62/18414\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other tumors involving the large bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare malignancies that are primary to the large bowel include Kaposi's sarcoma (KS), lymphomas, and carcinoid tumors. Disseminated KS can involve the colon in patients with AIDS, manifested as characteristic violaceous macules or nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=see_link&amp;anchor=H432027028#H432027028\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\", section on 'Gastrointestinal tract'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=see_link\">",
"     \"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary non-Hodgkin lymphoma of the large bowel most commonly arises in the cecum, right colon or rectum, and typically appears as a large solitary mass, although multiple polypoid lesions or diffuse involvement can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Colonic carcinoids develop at a younger age than adenocarcinomas, predominantly occurring in the appendix, rectum, and cecum. Appendiceal and rectal carcinoids appear as submucosal nodules and tend to be indolent, while primary colonic carcinoid tumors can present as large apple-core lesions, which are clinically aggressive and usually metastatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATTERNS OF SPREAD AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRCs can spread by lymphatic and hematogenous dissemination, as well as contiguous and transperitoneal spread. The most common metastatic sites are the regional lymph nodes, liver, and lungs. Because the venous drainage of the intestinal tract is via the portal system, the first site of hematogenous dissemination is usually liver, followed by lungs, bone, and many other sites, including (rarely) brain. However, tumors arising in the distal rectum may metastasize initially to the lungs because the inferior rectal vein drains into the inferior vena cava rather than into the portal venous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     TNM staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system of the",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) is the preferred staging system for CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. The older Duke's classification, including the Astler-Coller modification, is no longer used.",
"   </p>",
"   <p>",
"    The most recent 2010 TNM staging classification has a number of changes compared to the 2002 classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdivision of T4 lesions into T4a (tumor perforates the visceral peritoneum) and T4b (direct invasion or histologic adherence to other organs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      structures) (",
"      <a class=\"graphic graphic_figure graphicRef67081 \" href=\"mobipreview.htm?41/31/42485\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Further substaging of stage II into IIA (T3N0), IIB (T4aN0) and IIC (T4bN0) disease.",
"     </li>",
"     <li>",
"      N1 and N2 categories are subdivided according to the number of involved nodes.",
"     </li>",
"     <li>",
"      Extramural tumor deposits (TD) that are discontinuous from the leading edge of the cancer and lack evidence of a residual lymph node are classified N1c, if all microscopically identified regional nodes are otherwise negative; TD is also simultaneously recorded in the site-specific factor category Tumor Deposits. In other situations, the diagnostic interpretation of individual TDs is left to the discretion of the pathologist (ie, whether to classify as individually replaced lymph nodes (each counted separately and recorded in the pN category)) or not.",
"     </li>",
"     <li>",
"      Stage III disease groupings have been revised.",
"     </li>",
"     <li>",
"      M1 is subdivided into M1a (single metastatic site) and M1b (multiple sites).",
"     </li>",
"     <li>",
"      Although not used for staging, site-specific prognostic factors recommended for collection include pretreatment carcinoembryonic antigen (CEA) levels, the status of the circumferential resection margin, the presence or absence of perineural invasion, microsatellite instability, Kras gene analysis, and tumor regression grade (for tumors undergoing neoadjuvant therapy). These are discussed in detail in the sections that follow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic, endoscopic, and intraoperative findings are used to assign a clinical stage (cT, cN, cM), while assessment of pathologic stage (pT, pN, pM) requires gross pathologic or histopathologic examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The regional nodes differ for each large bowel segment, as illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef51172 \" href=\"mobipreview.htm?41/46/42731\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. Extraregional nodes are staged as metastases.",
"   </p>",
"   <p>",
"    If distant metastases are confirmed by pathologic assessment, assignment of pM1 is appropriate. Otherwise, no pM category is assigned. The designation pM0 does not exist, since it would denote pathologic confirmation of the absence of distant metastases anywhere in the body (a determination possible only at autopsy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     In situ cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, the term \"carcinoma in situ\" refers to cytologically malignant epithelial cells that do not penetrate the basement membrane or invade the underlying stroma. However, in the staging of CRC, the pTis category includes stromal invasion of malignant cells through the lamina propria including the muscularis mucosa. This is unique to the large bowel and justified because the colorectal mucosa, unlike the mucosa elsewhere in the GI tract and in other organs, lacks stromal lymphatics. As a result, tumors invading up to the muscularis mucosa lack access to the regional lymphatic vasculature and cannot metastasize via this route. It has been recommended that the terms \"intraepithelial carcinoma\" (without stromal invasion) and \"intramucosal carcinoma\" (with mucosal stromal invasion) be used to differentiate the two lesions included in the pTis category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/31\">",
"     31",
"    </a>",
"    ], but this distinction was not made in the 2010 TNM classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1641722874\">",
"    <span class=\"h3\">",
"     Posttherapy staging for rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriately selected patients, neoadjuvant chemoradiotherapy is associated with significant tumor response&nbsp;and downstaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/32\">",
"     32",
"    </a>",
"    ]. For these patients, prognosis is best determined by the posttreatment pathologic stage, which is assigned a yp prefix (ie, ypT, ypN) in the AJCC staging system. Among patients receiving initial chemoradiotherapy for rectal cancer, tumor eradication, as detected by pathologic examination of the&nbsp;resected specimen, is associated with a significantly better prognosis as compared to patients with residual tumor, particularly residual nodal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/33\">",
"     33",
"    </a>",
"    ]. Similarly, minimal residual disease is associated with a better prognosis than is gross residual&nbsp;disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link&amp;anchor=H3154313#H3154313\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Prognosis and the extent of tumor regression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Protocols for examination of specimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A protocol for the pathologic examination of carcinomas of the colon and rectum is available from the College of American Pathologists (CAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specimens from patients&nbsp;receiving neoadjuvant chemoradiation should be thoroughly sectioned, with careful examination of&nbsp;the tumor site. Although several grading systems for tumor response have been advocated, a three-point tumor&nbsp;regression grade has been shown to provide good interobserver reproducibility compared with five-grade&nbsp;schemas and to provide similar prognostic significance (",
"    <a class=\"graphic graphic_table graphicRef50210 \" href=\"mobipreview.htm?7/60/8139\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSTIC DETERMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important indicator of outcome after resection of CRC is the pathologic stage at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/25\">",
"     25",
"    </a>",
"    ]. Five-year survival stratified by tumor stage at diagnosis for rectal cancer using the 2010 AJCC staging criteria are illustrated in the table (",
"    <a class=\"graphic graphic_figure graphicRef60598 \" href=\"mobipreview.htm?0/63/1009\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. Five year survival rates tend to be somewhat higher for colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/36\">",
"     36",
"    </a>",
"    ]. Five-year survival stratified by tumor stage at diagnosis for colon cancer using the 2010 staging criteria is illustrated in the table (",
"    <a class=\"graphic graphic_figure graphicRef81414 \" href=\"mobipreview.htm?40/54/41824\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients receiving neoadjuvant (presurgical) treatment for rectal cancer, the posttreatment stage (given a yp designation in the AJCC staging system, see above) is a more accurate predictor of outcome than is the pretreatment clinical stage. &nbsp;",
"   </p>",
"   <p>",
"    TNM stage incorporates only elements of anatomic tumor extent, as determined by clinical and pathologic methods. An increasing number of independent prognostic factors are being identified, some of which may influence outcome predictions and treatment decisions. Among the factors that may be used in patient management and well supported in the literature are residual disease, histologic type and grade, CEA levels, extramural venous invasion, and submucosal vascular invasion in malignant polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1999, the CAP convened a Prognostic Factors Consensus Conference to evaluate the role of biologic, genetic, molecular, and other tissue-based factors in CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"     21",
"    </a>",
"    ]. Putative prognostic factors were grouped into categories that reflected the strength of the published evidence demonstrating their prognostic value. The following categories of prognostic factors were defined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Category I &mdash; Definitively proven to be of prognostic importance based upon evidence from multiple statistically robust published trials and generally used in patient management.",
"     </li>",
"     <li>",
"      Category IIA &mdash; Extensively studied biologically",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinically and shown to have prognostic value for outcome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      predictive value for response to therapy. These factors are of sufficient importance to be included in the pathology report, but their importance for clinical care is not yet validated in statistically robust studies.",
"     </li>",
"     <li>",
"      Category IIB &mdash; Shown to be promising in multiple studies; data insufficient for inclusion in Category I or IIA.",
"     </li>",
"     <li>",
"      Category III &mdash; Not yet sufficiently studied to determine their prognostic value.",
"     </li>",
"     <li>",
"      Category IV &mdash; Well studied and shown to have no prognostic significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Category I factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represent well-documented and clinically validated prognostic indicators for CRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Local tumor extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The local extent of disease (ie, depth of tumor penetration) independently influences survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. However, evaluation and reporting of features that determine the T category is variable, particularly the presence or absence of serosal involvement.",
"   </p>",
"   <p>",
"    Serosal involvement by tumor is an adverse pathologic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there exists significant confusion as to the definition of serosal \"involvement\". Histologic determination of serosal penetration is difficult, and conservative interpretation may lead to understaging of disease. As an example, cytologic examination of serosal scrapings reveals malignant cells in up to 26 percent of histologically defined pT3 specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histopathologic findings associated with peritoneal tumor involvement are heterogeneous and standard guidelines for their diagnostic interpretation are lacking. Local peritoneal involvement may be reflected by any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mesothelial inflammatory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperplastic reaction with tumor close to the serosal surface",
"     </li>",
"     <li>",
"      Tumor present at the serosal surface with an inflammatory reaction, mesothelial hyperplasia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erosion or ulceration",
"     </li>",
"     <li>",
"      Free tumor cells on the serosal surface within the peritoneum with underlying ulceration of the visceral peritoneum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All three types of local peritoneal involvement can be used to define serosal involvement (ie, a T4a tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]), and all adversely impact prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,40\">",
"     21,40",
"    </a>",
"    ]. The presence of free cells on the serosal surface is more likely than the other two forms of peritoneal involvement to predict intraperitoneal recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/40\">",
"     40",
"    </a>",
"    ]. In cases in which peritoneal involvement is uncertain, the lesser category (ie, T3) should be assigned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional lymph node involvement is one of the strongest predictors of outcome following surgical resection of CRC, second only to distant metastasis. Nodal spread is an indication for adjuvant therapy for both colon and rectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For both colon and rectal cancers, the incidence of regional node involvement is related both to the depth of transmural invasion of the primary tumor and to histologic grade. The number of involved lymph nodes is a strong predictor of outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30,43-46\">",
"     30,43-46",
"    </a>",
"    ]. Thus, the 2010 TNM classification stratifies nodal involvement according to the number of involved lymph nodes (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to the number of involved nodes, the total number of lymph nodes in the surgical specimen directly influences prognosis for both stage II (node-negative) and stage III (node-positive) disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. In a meta-analysis of 17 studies, the number of nodes examined per patient (with or without tumor involvement) significantly correlated with five-year disease-free and overall survival rates in patients with stage II and III disease (",
"    <a class=\"graphic graphic_table graphicRef60891 \" href=\"mobipreview.htm?32/34/33323\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a lymph node ratio (LNR, the ratio of metastatic to examined lymph nodes) has been suggested as a means of incorporating both the number of involved nodes and the total number examined into prognostic stratification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. As an example, five-year survival rates according to LNR from the INT-0089 trial are illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef68863 \" href=\"mobipreview.htm?18/41/19099\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 16 studies including 33,984 patients with stage III colon or rectal cancer concluded that the LNR was an independent predictor of overall, disease-free, and cancer-specific survival, and that the prognostic separation obtained by the LNR was superior to that of the number of positive nodes (ie, the N stage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/55\">",
"     55",
"    </a>",
"    ]. However, there is no consensus as to the optimal cutoff values defining the LNR category with the best outcomes. There are no prospective trials addressing this issue, and the values used in the available retrospective analyses vary widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/55\">",
"     55",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The reason for the relationship between total number of nodes in the specimen and outcomes is unclear. The most obvious explanation is that removal of more nodes increases the accuracy of staging. However, the strong association between total lymph node count and survival is not entirely explained by improvements in staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/52,56,57\">",
"     52,56,57",
"    </a>",
"    ]. The larger number of nodes may reflect the quality of the surgery and a more complete resection of the mesenteric pedicle. Alternatively, the differences between individual patients with colon cancer in terms of the number of lymph nodes present may reflect underlying biologic variability. As an example, tumor factors may stimulate lymph nodes to enlarge, reflecting immune system recognition of the tumor and more favorable survival outcomes with a higher number of lymph nodes that is independent of the number of metastatic lymph nodes. Such biological differences could contribute to the lack of association between average node counts, the frequency of nodal positivity, and survival in several hospital-based series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/58-61\">",
"     58-61",
"    </a>",
"    ] and in population-based analyses from the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/52,57\">",
"     52,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the disparate findings, guidelines from expert groups recommend at least 12 nodes be examined histologically to accurately determine nodal status; however, this number was derived empirically based upon older observational data that was not adjusted for variables such as T-stage and tumor grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,47,48,62\">",
"     21,47,48,62",
"    </a>",
"    ]. At least in the US, this \"benchmark\" is not being met in a sizable minority of patients, particularly those treated in community hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Rates of inadequate node retrieval seem to be improving over time in academic institutions (dropping from 38 to 5 percent between 1998 and 2005 in NCCN member institutions in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/65\">",
"     65",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    It has long been recognized that the frequency of detecting nodal disease is influenced by the methodology of node handling and assessment, which is quite variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/66\">",
"     66",
"    </a>",
"    ]. Surgical technique may contribute to variation in the number of nodes contained in a resection specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/67\">",
"     67",
"    </a>",
"    ], while diligence in the search for nodes, the use of fat clearing or other techniques to increase macroscopic visualization of nodes, and the pathologist's threshold for an acceptable number of evaluated nodes are variables in pathologic technique. If fewer than 12 nodes are present in the surgical specimen, additional techniques such as fat clearing should be used to try to increase the nodal yield [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relevance of the 12-node threshold has been questioned for patients with rectal cancer who have received neoadjuvant therapy prior to resection. Removal of 12 or more nodes is often not achievable after neoadjuvant therapy, and lower nodal counts in this setting have not been associated with understaging or inferior survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mesenteric nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 TNM system uses the term satellite tumor deposits to designate discrete rounded nodules of tumor of any size within the pericolic or perirectal fat or in adjacent mesentery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. They are considered the equivalent of nodal metastases (a lymph node replaced by tumor), even if they lack residual nodal architecture, and staged as N1c disease in the absence of other nodal metastases. Each should be counted separately in the involved lymph node count that determines pN status.",
"   </p>",
"   <p>",
"    The presence of these tumor deposits is a strong adverse prognostic feature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. The prognostic impact was addressed in a review of 786 patients with stage III CRC, 116 (15 percent) of whom had mesenteric nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/70\">",
"     70",
"    </a>",
"    ]. When the mesenteric nodules were considered separately from the primary tumor and regional nodal metastases for staging purposes, their presence worsened the prognosis of otherwise",
"    <span class=\"nowrap\">",
"     T/N0",
"    </span>",
"    disease to that of stage III disease, while for",
"    <span class=\"nowrap\">",
"     T/N+",
"    </span>",
"    disease, prognosis was similar to that of stage IIIC disease and better than for M1 (distant metastatic) disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nodal micrometastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated tumor cells (ITCs) are single tumor cells or small clusters of tumor cells measuring &le;0.2 mm in greatest dimension, seen either on histologic sections (H&amp;E stains) or using IHC methods, or any tumor that is detected only by non-histologic molecular methods such as reverse-transcriptase polymerase chain reaction (RT-PCR) to detect tumor-specific RNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of nodal micrometastases and their prognostic influence has been brought to the forefront by the development of sentinel node mapping and non-histologic techniques that detect small clusters or single tumor cells in lymph nodes. The use of these supplemental assays may result in upstaging of up to 50 percent of patients with CRC who have histologically negative nodes, depending upon the pT category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. However, the biological significance of these micrometastases is unclear; their detection has been shown to alter prognosis in some but not all studies. A systematic review and meta-analysis of 39 studies in node-negative colorectal cancer concluded that molecular detection of tumor cells in regional lymph nodes by any method was associated with significantly poorer overall survival (hazard ratio [HR] for death 2.2, 95% CI 1.43-3.40), disease-specific survival (HR 3.37, 95% CI 2.311-4.93), and disease-free survival (HR 2.24, 95% CI 1.57-3.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/77\">",
"     77",
"    </a>",
"    ]. While these data are intriguing, clinical validation in well-designed prospective studies will be required before any of these methods are adopted by pathologists for routine practice.",
"   </p>",
"   <p>",
"    At present, in the 2010 TNM staging classification, ITCs, whether detected by standard histologic techniques or IHC, are coded as pN0 (i+), and a tumor that is detected only by special molecular techniques such as RT-PCR is coded as pN0 (mol+) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vascular invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor invasion into veins or small non-muscularized vessels that may represent either post-capillary lymphatics or venules is an important prognostic determinant. Venous invasion, particularly of extramural veins, is an independent adverse prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/37,38,78,79\">",
"     37,38,78,79",
"    </a>",
"    ], as is lymphatic invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/79-84\">",
"     79-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous and angiolymphatic invasion should be reported as present or absent in all tumors, including malignant polyps, and the anatomic location specified as intramural or extramural. The diagnosis of LVI requires identification of tumor cells either within an endothelial-lined channel or surrounded by an elastic lamina. Small vessels not definitively interpreted as lymphatics or venules should be identified as angiolymphatic vessels. The CAP recommends that a single H&amp;E-stained section from each block of tumor be examined specifically for LVI; data are insufficient to recommend additional tissue levels, or the use of special IHC techniques to detect LVI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Residual tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual tumor after definitive therapy is an adverse prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,31,85,86\">",
"     21,31,85,86",
"    </a>",
"    ]. As an example, in a report of 152 patients with T4 colon cancers (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ), 10-year recurrence-free survival was significantly less for the 42 patients with incompletely resected cancers compared to those with fully resected T4N0 or T4 node-positive disease (19 versus 88 and 58 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The completeness of resection is largely dependent on the status of the circumferential resection margin, although the designation is global, and includes the transverse margins and other disease observed but not removed at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Circumferential (radial) margin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The R designation indicates local residual disease after therapy is complete and is appropriate only in the setting of M0 disease. The residual disease codes in the TNM staging system (R0, R1 and R2) are defined as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      R0 &mdash; Indicates complete tumor resection with all margins histologically uninvolved",
"     </li>",
"     <li>",
"      R1 &mdash; Incomplete tumor resection with microscopic surgical resection margin involvement (margins grossly uninvolved)",
"     </li>",
"     <li>",
"      R2 &mdash; Incomplete tumor resection with gross residual tumor that was not resected (primary tumor, regional nodes, or macroscopic margin involvement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An expanded R classification has been proposed that takes into account the minimal distance between tumor and resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/87\">",
"     87",
"    </a>",
"    ]. However, these modifications to the R classification have not yet been adopted by the AJCC and they are not a part of the 2010 edition of the TNM staging manual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Serum CEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum levels of the tumor marker carcinoembryonic antigen (CEA) should be routinely measured preoperatively in patients undergoing potentially curative resections for CRC for two reasons (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated preoperative CEA levels that do not normalize following surgical resection imply the presence of persistent disease and the need for further evaluation. The implications and management of the patient with a persistently elevated serum CEA level following surgical resection is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H12#H12\">",
"       \"Surveillance after colorectal cancer resection\", section on 'Carcinoembryonic antigen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preoperative CEA values are of prognostic significance. CEA levels &ge;5.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      have an adverse impact on survival that is independent of tumor stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/37,88-94\">",
"       37,88-94",
"      </a>",
"      ]. As an example, in a series of 17,910 patients diagnosed with colon cancer of any stage and reported to the Surveillance, Epidemiology and End Results (SEER) database in 2004, at a short median follow-up (27 months), an elevated preoperative CEA level was associated with a significantly increased risk of overall mortality (hazard ratio for death 1.60, 95% CI 1.46 to 1.76) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/94\">",
"       94",
"      </a>",
"      ]. Elevated CEA was an independent prognostic factor across all stages, and within each stage grouping, the prognosis of the subset of patients with elevated CEA was similar to or worse than a subset of patients identified as having a normal preoperative CEA level and who belonged to a higher AJCC stage grouping. An intriguing finding was that patients with node-negative disease and an elevated preoperative CEA level had a worse prognosis (HR for death 1.75, 95% CI 1.48 to 2.09) than did those with node-positive disease and a normal preoperative CEA level (HR for death 1.58, 95% CI 1.30 to 1.91). Interpretation of these results is compromised by the lack of data on adjuvant chemotherapy.",
"      <br/>",
"      <br/>",
"      These data suggest that preoperative CEA elevation should be incorporated into the conventional TNM staging system for colon cancer (as has been recommended by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"       21",
"      </a>",
"      ]). The 2010 TNM staging criteria does not include serum CEA in stage assignment, but recommends that the information be collected for prognostic value (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The data also support the view that decisions regarding adjuvant chemotherapy should take preoperative CEA levels into consideration. However, while patients with node-negative cancer and a high preoperative CEA could be considered at higher than average risk for recurrence after surgery alone, and this might influence the decision to administer adjuvant chemotherapy, particularly if other risk factors (eg, obstruction, perforation) are present, there are no data that directly support benefit for adjuvant chemotherapy in this particular setting. An expert panel convened by the American Society of Clinical Oncology (ASCO) in 2006 concluded that the data were insufficient to support the use of CEA to determine whether to treat a patient with adjuvant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/95\">",
"       95",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530323#H589530323\">",
"       \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Benefit of fluoropyrimidine-based chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Category IIA factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These factors were considered by the College of American Pathologists (CAP) to be of sufficient importance to be included in the pathology report, but their influence on clinical care has not yet been validated in statistically robust studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Tumor grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic grade reflects the degree of tumor differentiation and is a feature that has consistently been demonstrated to be a stage-independent prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/3,37,38,41,82,96-98\">",
"     3,37,38,41,82,96-98",
"    </a>",
"    ]. However, histologic grading is subjective, with significant interobserver variability and no single widely accepted uniformly used system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. The interpretation of grade can be based upon the entire tumor or by one single worst area, by the amount of gland formation alone, or by a combination of glandular formation and other structural or cytologic features.",
"   </p>",
"   <p>",
"    In the majority of studies, the prognostic significance of grade falls out on statistical analysis as a two-tiered stratification variable: low grade (well and moderately differentiated) versus high grade (poorly differentiated or undifferentiated). The CAP and",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    have both recommended the adoption of a two-tiered grading system for CRC and the use of gland formation as the only feature by which grade is assessed (ie, &lt;50 percent gland formation represents high-grade disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,30\">",
"     21,30",
"    </a>",
"    ]. A two-tiered system with a well defined cut-point would be expected to reduce interobserver variation while preserving (or improving) the prognostic power of grade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Circumferential (radial) margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circumferential resection margin (CRM) corresponds to the surgically dissected nonperitonealized surface of the specimen. It refers to any aspect of the colorectum that is not covered (or partially covered, as with the ascending and descending colon and rectosigmoid) by a serosal layer of mesothelial cells and that must be dissected from the retroperitoneum (or subperitoneum in order to remove the viscus). For mid and distal rectal cancers that are entirely subperitoneal in location, the entire external surface of the specimen is considered a CRM.",
"   </p>",
"   <p>",
"    In contrast, for colonic segments that are completely encased by a peritonealized (serosal) surface (eg, cecum, transverse, and sigmoid colon), the only surgical margin that is surgically dissected is the mesenteric margin unless the cancer is adherent to or invading an adjacent organ or structure. In such cases, the CRM is a relevant radial margin only when the point of deepest tumor penetration is on the mesenteric aspect of the bowel and extends to the surface of this margin with or without serosal penetration. These concepts are illustrated in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef67081 \" href=\"mobipreview.htm?41/31/42485\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For rectal cancer, the quality of the surgical technique and the status of the CRM is one of most important predictive factors for both local and distant recurrence as well as survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/101-106\">",
"     101-106",
"    </a>",
"    ]. Total mesorectal excision (TME) with adequate surgical clearance around the penetrating edge of the tumor decreases the rate of local relapse. With this approach, all mesorectal soft tissues encasing the rectum (which includes the mesentery and all regional nodes) are removed intact, and the circumferential surface is the mesorectal fascia.",
"   </p>",
"   <p>",
"    In the analysis of the surgical specimen, the distance between the closest leading edge of the tumor and the CRM should be measured and recorded, in mm. There is ongoing debate as to when to call the CRM positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/107,108\">",
"     107,108",
"    </a>",
"    ], but most consider it positive if the distance between the deepest point of penetration by the tumor and the CRM is &le;1 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/101,109-111\">",
"     101,109-111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87590296#H87590296\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Total mesorectal excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although studies defining the relationship between CRM status and outcome are lacking for colonic cancers, it is reasonable to expect a greater risk for local tumor recurrence in any nonperitonealized segment, as with rectal cancer. For patients who have not received radiation therapy preoperatively, CRM positivity represents an indication for postoperative radiation therapy, regardless of the local tumor extent, particularly for rectal cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Adjuvant RT alone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Tumor regression after neoadjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system was initially devised for tumors that had not been previously treated. Preoperative or neoadjuvant therapy is increasingly employed for rectal tumors. Compared to initial surgery followed by adjuvant therapy, neoadjuvant therapy is associated with less long-term treatment-related toxicity, and in some cases, preservation of sphincter function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic TNM stage of disease in the resected specimen following neoadjuvant treatment is classified differently (the ypTNM classification) (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) as compared to tumors that have not received neoadjuvant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, the degree of tumor regression to preoperative treatment is an important prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/34,112\">",
"     34,112",
"    </a>",
"    ], and should be reported in the pathology report. There are",
"    <span class=\"nowrap\">",
"     CAP/AJCC",
"    </span>",
"    guidelines for assessing tumor regression grade (",
"    <a class=\"graphic graphic_table graphicRef50210 \" href=\"mobipreview.htm?7/60/8139\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link&amp;anchor=H12#H12\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Versus adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Category IIB factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are prognostic factors that are promising in multiple studies, but the data are insufficient for inclusion in Category I or IIA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Histologic type",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, histologic type has not proven to be an independent prognostic factor for colorectal adenocarcinomas with the exception of a few high grade subtypes (eg, signet ring, poorly differentiated, or undifferentiated tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/10,41,113-117\">",
"     10,41,113-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least some data suggest that mucinous tumors of the rectum (but not the colon) are independently associated with worse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/117\">",
"     117",
"    </a>",
"    ]. However, mucinous tumors, particularly right-sided tumors, are associated with the microsatellite instability pathway, and only a limited number of studies have evaluated the influence of histologic subtype after stratification by the presence or absence of microsatellite instability (MSI) (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Mismatch repair deficiency and tumor infiltrating lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in one of several DNA mismatch repair genes are found in hereditary nonpolyposis colorectal cancer (HNPCC) and in 15 to 20 percent of sporadic colon cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic genetic signature of tumors with deficient mismatch repair is a high number of DNA replication errors (RER+) and high levels of DNA microsatellite instability (MSI-H), defined as instability in &ge;30 percent of microsatellite loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. The term MSI refers to the expansion or contraction of short repeated DNA sequences that are caused by the insertion or deletion of repeated units.",
"   </p>",
"   <p>",
"    Although these tumors are often poorly differentiated, MSI-H is associated with longer survival than either MSI-low (MSI-L) or microsatellite-stable (MSS), both in HNPCC and in sporadic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/119-127\">",
"     119-127",
"    </a>",
"    ]. The biological basis for this finding is unknown. MSI is one of the clinically significant prognostic factors that is recommended for collection in the 2010 TNM staging criteria for CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/30\">",
"     30",
"    </a>",
"    ]. The presence of MSI-H is of potential clinical relevance in making treatment decisions. In addition to the better prognosis afforded by the presence of mismatch repair deficiency in an individual tumor, the bulk of available data support the view that adjuvant 5-FU-based chemotherapy is less beneficial for patients with MSI-positive tumors. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530415#H589530415\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Molecular prognostic and predictive factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large bowel tumors with MSI-H have distinctive histologic features; they are more common in the right colon, are more often of the mucinous, signet ring cell or medullary histologic type, are poorly differentiated, and have a brisk lymphocytic infiltrate or are rimmed by a Crohn-like, germinal center-producing lymphoid reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/119,125,128-131\">",
"     119,125,128-131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These histologic features have been used to select patients with colon cancer who might have HNPCC, and therefore, warrant genetic testing. However, while having one or more of these pathologic features can be used to predict the probability of bearing an MSI-high they are insufficiently accurate for the selection of patients who warrant mutation testing for Lynch syndrome. The subject of identification of individuals with Lynch syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The presence of tumor-infiltrating lymphocytes has been a favorable prognostic factor in many but not all studies. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Peritumoral fibrosis and inflammatory response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Lymphoid infiltration may represent a favorable prognostic marker because of its association with MSI. Tumors containing numerous lymphoid cells, as noted above, frequently have mutations in DNA mismatch repair genes and MSI-H [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/132-135\">",
"     132-135",
"    </a>",
"    ]. Medullary carcinoma, a unique histologic type of CRC that is almost always microsatellite-unstable and has a strong association with HNPCC, is characterized by intratumoral lymphocytic infiltrates. However, in at least one report, MSI-H and intratumoral lymphocytic infiltration were each independent prognostic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further large studies with multivariate analysis that differentiate between intratumoral and peritumoral lymphocytic infiltration are needed for confirmation of these data before the presence of lymphocytic infiltration is routinely accepted as a standard prognostic indicator for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     18q deletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allelic loss of a region on the long arm of chromosome 18 occurs commonly in CRC. This region encompasses three domains (DCC, SMAD4 and SMAD2) that may influence intestinal tumorigenesis; the most well studied is the DCC (Deleted in Colon Cancer) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is suggestive evidence of an association between 18q loss and the natural history of CRC. Loss of heterozygosity (LOH) at 18q",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lack of expression of its encoded protein has been linked to an inferior prognosis for patients with both node-negative as well as node-positive CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/123,137-146\">",
"     123,137-146",
"    </a>",
"    ]. In one study, patients having stage II disease with 18q LOH behaved similarly to those with node-positive disease, while the prognosis of patients with stage II disease who were without 18q LOH was similar to those with stage I disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, questions remain as to whether 18q loss is an independent predictor of outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/147-151\">",
"     147-151",
"    </a>",
"    ]. As an example, 18q LOH is inversely associated with microsatellite instability, a favorable prognostic factor (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Mismatch repair deficiency and tumor infiltrating lymphocytes'",
"    </a>",
"    above). There are conflicting data as to whether 18q LOH has any prognostic implication independent of MSI status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, among patients with microsatellite-stable stage III cancer, the loss of an 18q allele was associated with a 2.75-fold higher risk of dying from CRC as compared to those who retained 18q alleles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, in a series of 555 non-MSI-high CRCs stage I through IV derived from two prospective cohort studies, five-year CRC-specific survival was similar in those with and without 18q LOH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/151\">",
"       151",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The small number and retrospective nature of studies which found 18q status to be an independent predictor of survival led an expert panel convened by ASCO to conclude that it was premature to use 18q status to determine prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, DCC loss is the most promising of the available molecular prognostic markers (see",
"    <a class=\"local\" href=\"#H31\">",
"     'All other molecular markers'",
"    </a>",
"    below). Further studies on well-characterized patient populations with multivariate analysis are needed to determine the clinical utility of this marker before it can be used in the clinical decision-making process.",
"   </p>",
"   <p>",
"    If validated, molecular stratification by factors such as DCC loss could be particularly helpful in patients with node-negative colon cancer, for whom adjuvant chemotherapy has not proven beneficial. If patients with node-negative disease and DCC loss represent a subset with particularly poor prognosis, then this group could be specifically targeted for additional therapeutic strategies. Randomized controlled trials are underway to validate this principle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Tumor border",
"    </span>",
"    &nbsp;&mdash;&nbsp;For CRC, the configuration of the tumor at the advancing edge (tumor border) has been shown to have prognostic significance that is independent of stage and may predict liver metastasis. Specifically, an irregular, infiltrating pattern of growth as opposed to a smooth pushing (expansile) border has been demonstrated to be an independent adverse prognostic factor by several multivariate analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/115,152,153\">",
"     115,152,153",
"    </a>",
"    ]. The following characteristics are indicative of an infiltrating border [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to define the limits of tumor invasion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distinguish host tissue from malignant tissue by naked eye examination of a microscopic slide of the tumor border",
"     </li>",
"     <li>",
"      On microscopic examination of the tumor border, dissection of tumor through the full thickness of the muscularis propria without a stromal response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dissection of mesenteric adipose tissue by small glands or irregular clusters or cords of cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perineural invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumor \"budding\" is another specific feature found at the tumor border that is defined as microscopic clusters of undifferentiated cancer cells just ahead of the invasive front of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/154\">",
"     154",
"    </a>",
"    ] and has also been referred to as \"focal dedifferentiation\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/84,100\">",
"     84,100",
"    </a>",
"    ]. It may be seen in an otherwise well- or moderately-differentiated tumor. Some data suggest that it may be of greater prognostic value than grade and may have prognostic value that is independent of overall tumor border configuration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/100,154\">",
"     100,154",
"    </a>",
"    ]. It is predictive of regional lymph node metastasis in abdominoperineal resection specimens of T1 and superficial T2 rectal cancers, suggesting that it may be useful as an indicator for patients at risk of recurrence after local excision (transanal disk excision) alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the data are suggestive, in order to definitively evaluate the prognostic importance of tumor border configuration and tumor budding in CRC, statistically robust studies with multivariate analysis and standardized criteria for pathologic assessment will be required. Nevertheless, it is recommended that pathologic assessment of tumor border configuration be routinely reported for transmurally invasive CRCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,31\">",
"     21,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27253668\">",
"    <span class=\"h3\">",
"     Perineural invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several studies, perineural invasion alone was associated with a poor prognosis in multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/38,82,155-158\">",
"     38,82,155-158",
"    </a>",
"    ]. Nevertheless, it is still considered a category IIB factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,31\">",
"     21,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Category III factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These factors are not yet sufficiently studied to determine their prognostic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     DNA content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in DNA content (aneuploidy) has been independently associated with an adverse prognosis in many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/159-165\">",
"     159-165",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/166-170\">",
"     166-170",
"    </a>",
"    ]. Tumoral DNA content can be obtained by flow cytometry or image analytic techniques. Flow cytometry is somewhat impractical in routine settings and is limited by the lack of procedure standardization (particularly for non-fresh material) and quality assurance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/171\">",
"     171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, estimating DNA content in individual tumor cells by image analysis is applicable to formalin-fixed, paraffin-embedded material. However, as noted above, contrasting results have been noted. As an example, in one series of 20 patients with recurrent Duke's B2 colonic carcinoma and 20 controls with nonrecurrent Duke's B2 cancers who were matched for age, sex, tumor site, and grade of differentiation, aneuploidy was twice as common in those tumors destined to recur (80 versus 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/159\">",
"     159",
"    </a>",
"    ]. However, in a second series of 137 patients with resected CRC, tumor cell DNA content had no independent influence on disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like flow cytometry, image analysis of DNA ploidy lacks standardization of technique and interpretation, particularly since there is marked intratumoral heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/160\">",
"     160",
"    </a>",
"    ]. An expert panel convened by ASCO to assess tumor markers in CRC recommended against the use of DNA ploidy to determine prognosis of early stage CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/95\">",
"     95",
"    </a>",
"    ]. Larger studies evaluating the prognostic impact of DNA content using consistent and reproducible techniques are needed, including comparative evaluation of available methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     All other molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of a wide variety of promising and potentially clinically applicable molecular markers have been studied in CRC. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor suppressor genes (LOH 1p, LOH 8p; LOH 5q; LOH 17p)",
"     </li>",
"     <li>",
"      Oncogenes (K-ras; c-myc)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Apoptosis/cell",
"      </span>",
"      suicide-related genes (bcl-2;BAX;Apoptosis protease activating factor-1)",
"     </li>",
"     <li>",
"      DNA synthesis-related genes (thymidylate synthetase; thymidine phosphorylase)",
"     </li>",
"     <li>",
"      Growth factors and growth factor receptor genes (TGFa; TGFb; HER2 [c-erbB-2]; EGF-R)",
"     </li>",
"     <li>",
"      Cyclins and cyclin dependent kinase inhibitor genes (p27; p21)",
"     </li>",
"     <li>",
"      Angiogenesis-related genes (vascular endothelial growth factor [VEGF])",
"     </li>",
"     <li>",
"      Adhesion molecule and glycoprotein genes (CD44; E-cadherin [CDH1]; sialo-Tn antigen)",
"     </li>",
"     <li>",
"      Matrix metalloproteinases and their inhibitors (MMPs; urokinase-type plasminogen activator)",
"     </li>",
"     <li>",
"      Metastasis suppressor genes (nm23-H1)",
"     </li>",
"     <li>",
"      Overexpression of microRNA",
"     </li>",
"     <li>",
"      Epigenetic aberrations such as methylation levels",
"     </li>",
"     <li>",
"      Peroxisome proliferator-activated receptor-gamma (PPARG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The independent influence of these markers on prognosis remains unproven. Variability in assay methodology, conflicting results from various studies examining the same factor, and the prevalence of multiple small studies that lack statistically robust, multivariate analyses all contribute to the lack of conclusive data.",
"   </p>",
"   <p>",
"    As an example, p53, which probably represents the most widely studied gene in CRC, has been analyzed according to LOH, protein overexpression by immunohistochemistry (IHC), and detection of mutations by either direct sequencing or single strand polymorphism analysis. Despite a large number of publications and a systematic review, the impact of p53 abnormalities on prognosis in CRC remains uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/172\">",
"     172",
"    </a>",
"    ]. Even among reports that use a single assay system, the reagents used vary considerably, confounding interpretation of the results.",
"   </p>",
"   <p>",
"    Another potential confounder is that different mutations within the same gene may exert disparate prognostic influences As an example, K-Ras mutations involving either codon 12 or 13 can be identified in 12 to 75 percent of tumors; they have been independently associated with a worse prognosis in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/173-175\">",
"     173-175",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/176-178\">",
"     176-178",
"    </a>",
"    ]. The multicenter RASCAL study evaluated the prognostic significance of mutations in codon 12 or 13 in 2721 patients from 13 countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/174\">",
"     174",
"    </a>",
"    ]. In multivariate analysis, only codon 12 mutations were independently associated with an increased risk of recurrence and death. However, in a later analysis that was expanded to include 4268 patients and 12 possible mutations within codons 12 and 13, only one specific mutation on codon 12, found in 9 percent of the cohort, was significantly associated with an adverse outcome and only in patients with node-positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before any of these markers can be incorporated into clinically meaningful prognostic stratification systems, more studies are required using multivariate analysis, well-characterized patient populations, reproducible and current methodology, and standardized reagents. Guidelines to standardize reporting of tumor marker studies have been proposed by an international group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     K-ras and benefit from EGFR-targeted treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the uncertainty surrounding its prognostic utility, mutations in K-ras appear to have value as predictive factors for lack of response to certain therapies. Activating K-ras mutations, which are detected in approximately 40 to 45 percent of CRCs, are associated with resistance to agents that target the epidermal growth factor receptor (EGFR), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    . This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Microvessel density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratumoral microvessel density (MVD) is a reflection of tumor-induced angiogenesis. MVD has been independently associated with shorter survival in some but not all studies. A meta-analysis of all studies relating MVD expression to prognosis concluded that at least some of the variability could be explained by the different methods of MVD assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/181\">",
"     181",
"    </a>",
"    ]. There was a significant inverse correlation between immunohistochemical expression and survival when MVD was assessed using antibodies against CD31 or CD34, but not factor VIII.",
"   </p>",
"   <p>",
"    There is a need for evaluation of MVD in large studies of prognostic factors using multivariate analysis; however, standard guidelines for staining, evaluation, and interpretation of MVD are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Cell surface molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of cellular proteins and carbohydrates have been studied to date, but the analysis of individual factors is limited. No factor has been studied sufficiently in clinical trials to meet the criteria for Category I, IIA or IIB factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21,31\">",
"     21,31",
"    </a>",
"    ]. These include but are not limited to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I or II HLA molecules",
"     </li>",
"     <li>",
"      CA 19-9 and CA 72-4",
"     </li>",
"     <li>",
"      Sialyl Lex or sialosyl-Tn",
"     </li>",
"     <li>",
"      Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 2 (PAI-2)",
"     </li>",
"     <li>",
"      Glycoprotein 72",
"     </li>",
"     <li>",
"      P-glycoprotein (MDR gene product)",
"     </li>",
"     <li>",
"      MUC-1 mucin",
"     </li>",
"     <li>",
"      E-cadherin, integrins, type IV collagen, gelatinase B (MMP-9), laminin, and tenascin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Peritumoral fibrosis and inflammatory response",
"    </span>",
"    &nbsp;&mdash;&nbsp;A desmoplastic stromal response is common in invasive CRCs and is responsible for their typical hard consistency. In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/40,115\">",
"     40,115",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/182,183\">",
"     182,183",
"    </a>",
"    ], fibrosis is an independent adverse prognostic factor.",
"   </p>",
"   <p>",
"    Few studies have specifically addressed the prognostic significance of tumor-associated granulocytic or mixed cellular inflammation (as opposed to an immune response in which lymphocytes and plasma cells predominate). In all three, this feature was independently associated with a better outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/115,184,185\">",
"     115,184,185",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in many other types of cancer, the presence of tumor infiltrating lymphocytes is a favorable prognostic factor in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/186-193\">",
"     186-193",
"    </a>",
"    ]. In particular, a high density of CD8+ T cells and CD45RO+ cells (both CD4+ and CD8+ lymphocytes that have been exposed to antigen, ie, memory cells) within these lymphoid populations has been associated with the absence of pathologic evidence of early metastatic invasion, earlier stage, and improved patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/187,189,190,192\">",
"     187,189,190,192",
"    </a>",
"    ]. These data have led some to suggest that this response indicates that defensive host mechanisms were operative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/187\">",
"     187",
"    </a>",
"    ]. However, there are no direct data to support such a hypothesis.",
"   </p>",
"   <p>",
"    More recently, a high density of a different type of T cell, regulatory T cells (which are characterized by the CD4+CD25+ phenotype and thought to modulate the antitumor immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/194\">",
"     194",
"    </a>",
"    ]) was found to have a stronger prognostic significance in colorectal cancer than either infiltrating CD8+ or CD45RO+ cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/195\">",
"     195",
"    </a>",
"    ]. In the future, density of these T regulatory cells may help to refine the prognostication of early stage CRC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=see_link&amp;anchor=H1232172#H1232172\">",
"     \"Normal B and T lymphocyte development\", section on 'Regulatory T cells (Tregs)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Focal neuroendocrine differentiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although extensive neuroendocrine differentiation is an adverse prognostic factor in CRC, the significance of scattered or focal neuroendocrine differentiation is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/196-199\">",
"     196-199",
"    </a>",
"    ]. In one report, a significantly worse prognosis was found if more than 2 percent of cells stained positive for neuroendocrine markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/198\">",
"     198",
"    </a>",
"    ]. Assessment should be made on routine H &amp; E sections; the data are insufficient to recommend the use of special stains (ie, chromogranin, neuron-specific enolase, or synaptophysin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Proliferative activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proliferative rate within an individual tumor can be assessed by analysis of argyrophilic nucleolar organizing regions (AgNORs), mitotic index, S phase analysis by flow cytometry, and IHC for markers of proliferation, such as the Ki 67 nuclear antigen and proliferating cell nuclear antigen (PCNA).",
"   </p>",
"   <p>",
"    The prognostic significance of AgNOR analysis in CRC is unclear. An association between AgNORs and outcome has been shown in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/184\">",
"     184",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/200,201\">",
"     200,201",
"    </a>",
"    ]. Results may depend both upon the technique used to visualize AgNORs and the method of interpretation (ie, stratification of AgNOR results by intracellular location",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    configuration versus density alone).",
"   </p>",
"   <p>",
"    Although assessment of the mitotic index is a simple technique and high rates correlate with inferior survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/202\">",
"     202",
"    </a>",
"    ], it is seldom applied to carcinomas in general or CRC specifically. Flow cytometry proliferation analysis (percent S phase) and IHC are more commonly used to assess proliferation in CRC.",
"   </p>",
"   <p>",
"    The data relating S phase fraction by flow cytometry to prognosis in CRC are inconsistent. Some studies report high S phase to be an independent prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/159,160,203\">",
"     159,160,203",
"    </a>",
"    ] while others do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/204,205\">",
"     204,205",
"    </a>",
"    ]. These inconsistent results led an expert panel convened by ASCO to recommend against the use of S phase analysis to determine prognosis of operable colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCNA is an attractive alternative to S phase analysis by flow cytometry. In one report that limited the analysis to tumor cells at the invasive margin, there was a linear relationship between PCNA labeling index (LI) and both recurrence and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/206\">",
"     206",
"    </a>",
"    ]. However, others have failed to demonstrate an independent prognostic significance for PCNA LI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/207\">",
"     207",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCNA can also be evaluated by IHC, although considerable variability has been reported using the PC10 anti-PCNA monoclonal antibody.",
"    <span class=\"nowrap\">",
"     MIB-1/Ki",
"    </span>",
"    67 analysis may be superior for routine formalin-fixed colon specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/165,208\">",
"     165,208",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Category IV factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the factors that have been well studied, and determined not to exert a significant impact on prognosis are tumor size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/38,41,81\">",
"     38,41,81",
"    </a>",
"    ] and gross tumor configuration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/41,114\">",
"     41,114",
"    </a>",
"    ]. However, newer data suggest that tumor size may be an adverse prognostic factor for colon but not rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/34/41514/abstract/209\">",
"     209",
"    </a>",
"    ]. Overall size &gt;4.5 cm was an independent predictor of poor outcome, but the optimal cut-point for size indicative of an adverse prognosis varied with anatomic location in the colon, decreasing from right to left.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Prognostic molecular profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling has identified molecular signatures, such as the 12-gene recurrence score (Oncotype DX Colon Cancer Assay) or an 18-gene classifier (ColoPrint), that may augment conventional prognostic indicators in their ability to predict colon cancer outcomes among patients with node-negative (stage II) disease. However, before these tests can be adopted for widespread clinical use, validation in prospective clinical trials is needed to assess their prognostic and predictive utility (ie, their ability to predict which patients with stage II disease would be predicted to benefit from adjuvant chemotherapy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530415#H589530415\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Molecular prognostic and predictive factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the enormous number of correlative studies exploring the prognostic significance of various histologic, molecular, and clinical features, the pathologic stage at diagnosis remains the best indicator of long-term prognosis for both colon and rectal cancer. The most important characteristics are the presence of distant metastases, local tumor extent, nodal positivity (particularly the number of involved lymph nodes), and residual disease. Further stratification of outcome can be achieved by the identification of patients with lymphovascular invasion, and a high preoperative serum CEA level.",
"   </p>",
"   <p>",
"    Preliminary studies suggest that the molecular features of microsatellite instability and DCC loss may also influence outcome, independent of stage at presentation. However, until large, statistically robust studies are completed with multivariate analysis of an array of potential prognostic factors and their interaction with each other, neither these nor other molecular or genetic markers should be used routinely to develop treatment recommendations or to estimate prognosis in patients with resected CRC.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/2\">",
"      Carraro PG, Segala M, Cesana BM, Tiberio G. Obstructing colonic cancer: failure and survival patterns over a ten-year follow-up after one-stage curative surgery. Dis Colon Rectum 2001; 44:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/3\">",
"      Griffin MR, Bergstralh EJ, Coffey RJ, et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987; 60:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/4\">",
"      Katoh H, Yamashita K, Wang G, et al. Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer. Ann Surg Oncol 2011; 18:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/5\">",
"      Langevin JM, Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. Am J Surg 1984; 147:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/6\">",
"      Passman MA, Pommier RF, Vetto JT. Synchronous colon primaries have the same prognosis as solitary colon cancers. Dis Colon Rectum 1996; 39:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/7\">",
"      Fante R, Roncucci L, Tamassia MG, et al. Frequency and clinical features of multiple tumors of the large bowel in the general population and in patients with hereditary colorectal carcinoma. Cancer 1996; 77:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/8\">",
"      Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol 2011; 29:4401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/9\">",
"      Green JB, Timmcke AE, Mitchell WT, et al. Mucinous carcinoma--just another colon cancer? Dis Colon Rectum 1993; 36:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/10\">",
"      Secco GB, Fardelli R, Campora E, et al. Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. Oncology 1994; 51:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/11\">",
"      Minsky BD, Mies C, Rich TA, et al. Colloid carcinoma of the colon and rectum. Cancer 1987; 60:3103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/12\">",
"      Minsky BD. Clinicopathologic impact of colloid in colorectal carcinoma. Dis Colon Rectum 1990; 33:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/13\">",
"      Consorti F, Lorenzotti A, Midiri G, Di Paola M. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/14\">",
"      Shin US, Yu CS, Kim JH, et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol 2011; 18:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/15\">",
"      Nissan A, Guillem JG, Paty PB, et al. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis Colon Rectum 1999; 42:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/16\">",
"      Psathakis D, Schiedeck TH, Krug F, et al. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. Dis Colon Rectum 1999; 42:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/17\">",
"      Frizelle FA, Hobday KS, Batts KP, Nelson H. Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis Colon Rectum 2001; 44:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/18\">",
"      Masoomi H, Ziogas A, Lin BS, et al. Population-based evaluation of adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum 2012; 55:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/19\">",
"      Petrelli NJ, Valle AA, Weber TK, Rodriguez-Bigas M. Adenosquamous carcinoma of the colon and rectum. Dis Colon Rectum 1996; 39:1265.",
"     </a>",
"    </li>",
"    <li>",
"     Jass JR, Sobin LH. Histological typing of intestinal tumours. In: WHO International Histological Classification of Tumours, 2nd, Springer-Verlag, Berlin-New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/21\">",
"      Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/22\">",
"      Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997; 21:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/23\">",
"      Guerrieri C, Fr&aring;nlund B, Fristedt S, et al. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol 1997; 28:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/24\">",
"      Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000; 13:962.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/26\">",
"      Friedman SL, Wright TL, Altman DF. Gastrointestinal Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Endoscopic and autopsy findings. Gastroenterology 1985; 89:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/27\">",
"      Busch E, Rodriguez-Bigas M, Mamounas E, et al. Primary colorectal non-Hodgkin's lymphoma. Ann Surg Oncol 1994; 1:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/28\">",
"      Marshall JB, Bodnarchuk G. Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993; 16:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/29\">",
"      Spread C, Berkel H, Jewell L, et al. Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994; 37:482.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/31\">",
"      Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/32\">",
"      Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/33\">",
"      Gavioli M, Luppi G, Losi L, et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 2005; 48:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/34\">",
"      Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/35\">",
"      Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/36\">",
"      O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/37\">",
"      Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/38\">",
"      Chapuis PH, Dent OF, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985; 72:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/39\">",
"      Tominaga T, Sakabe T, Koyama Y, et al. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer 1996; 78:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/40\">",
"      Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/41\">",
"      Newland RC, Dent OF, Lyttle MN, et al. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994; 73:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/42\">",
"      Zeng Z, Cohen AM, Hajdu S, et al. Serosal cytologic study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer 1992; 70:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/43\">",
"      Wolmark N, Fisher B, Wieand HS. The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials. Ann Surg 1986; 203:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/44\">",
"      Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002; 236:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/45\">",
"      Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/46\">",
"      Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006; 244:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/47\">",
"      Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/48\">",
"      Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/49\">",
"      Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006; 24:3570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/50\">",
"      Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/51\">",
"      Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007; 13:6862s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/52\">",
"      Baxter NN, Ricciardi R, Simunovic M, et al. An evaluation of the relationship between lymph node number and staging in pT3 colon cancer using population-based data. Dis Colon Rectum 2010; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/53\">",
"      Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23:8706.",
"     </a>",
"    </li>",
"    <li>",
"     Meyers MO, Hollis DR, Mayer RJ, et al. Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114 (abstract). J Clin Oncol 2007; 25:165s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/55\">",
"      Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review. Ann Surg Oncol 2010; 17:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/56\">",
"      Moore J, Hyman N, Callas P, Littenberg B. Staging error does not explain the relationship between the number of lymph nodes in a colon cancer specimen and survival. Surgery 2010; 147:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/57\">",
"      Parsons HM, Tuttle TM, Kuntz KM, et al. Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA 2011; 306:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/58\">",
"      Wong SL, Ji H, Hollenbeck BK, et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007; 298:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/59\">",
"      Tsikitis VL, Larson DL, Wolff BG, et al. Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. J Am Coll Surg 2009; 208:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/60\">",
"      Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/61\">",
"      Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 2006; 93:439.",
"     </a>",
"    </li>",
"    <li>",
"     National voluntary consensus standards for quality of cancer care from the National Quality Forum available online at www.qualityforum.org/pdf/cancer/txAppA-Specifications_web.pdf (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/63\">",
"      Baxter NN, Virnig DJ, Rothenberger DA, et al. Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 2005; 97:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/64\">",
"      Bilimoria KY, Bentrem DJ, Stewart AK, et al. Lymph node evaluation as a colon cancer quality measure: a national hospital report card. J Natl Cancer Inst 2008; 100:1310.",
"     </a>",
"    </li>",
"    <li>",
"     Chang GJ, Taylor SH, Rodriguez-Bigas MA, Skibber JM, et al. The twelve lymph node standard in colon cancer: Can it be achieved? (abstract 448). Data presented at the 2008 ASCO GI Cancers Symposium, Orlando, FL, January 24, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/66\">",
"      Morris EJ, Maughan NJ, Forman D, Quirke P. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. J Clin Oncol 2007; 25:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/67\">",
"      West NP, Hohenberger W, Weber K, et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010; 28:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/68\">",
"      Govindarajan A, G&ouml;nen M, Weiser MR, et al. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol 2011; 29:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/69\">",
"      Goldstein NS, Turner JR. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: markers of reduced disease free survival and intra-abdominal metastases and their implications for TNM classification. Cancer 2000; 88:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/70\">",
"      Lo DS, Pollett A, Siu LL, et al. Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer 2008; 112:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/71\">",
"      Belt EJ, van Stijn MF, Bril H, et al. Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Ann Surg Oncol 2010; 17:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/72\">",
"      Nagtegaal ID, Tot T, Jayne DG, et al. Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol 2011; 29:2487.",
"     </a>",
"    </li>",
"    <li>",
"     Waldman S, Hyslop T, Schulz S, et al. A prospective multicenter study of guanyl cyclase C (GCC), quantified by the reverse transcriptase-polymerase chain reaction (qRT-PCR), as a prognostic marker of occult metastases in lymph nodes of pN0 colorectal cancer patients (abstract). J Clin Oncol 2008; 26:580s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/74\">",
"      Paramo JC, Summerall J, Wilson C, et al. Intraoperative sentinel lymph node mapping in patients with colon cancer. Am J Surg 2001; 182:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/75\">",
"      Bernini A, Spencer M, Frizelle S, et al. Evidence for colorectal cancer micrometastases using reverse transcriptase-polymerase chain reaction analysis of MUC2 in lymph nodes. Cancer Detect Prev 2000; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/76\">",
"      Bilchik AJ, Nora DT, Sobin LH, et al. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol 2003; 21:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/77\">",
"      Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/78\">",
"      Mulcahy HE, Skelly MM, Husain A, O'Donoghue DP. Long-term outcome following curative surgery for malignant large bowel obstruction. Br J Surg 1996; 83:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/79\">",
"      Betge J, Pollheimer MJ, Lindtner RA, et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012; 118:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/80\">",
"      Takebayashi Y, Aklyama S, Yamada K, et al. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/81\">",
"      Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/82\">",
"      Hermanek P, Guggenmoos-Holzmann I, Gall FP. Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification. Dis Colon Rectum 1989; 32:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/83\">",
"      Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion. Cancer 1988; 61:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/84\">",
"      Minsky BD, Mies C, Rich TA, Recht A. Lymphatic vessel invasion is an independent prognostic factor for survival in colorectal cancer. Int J Radiat Oncol Biol Phys 1989; 17:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/85\">",
"      Willett CG, Goldberg S, Shellito PC, et al. Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? Cancer J Sci Am 1999; 5:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/86\">",
"      Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/87\">",
"      Wittekind C, Compton C, Quirke P, et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 2009; 115:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/88\">",
"      Wolmark N, Fisher B, Wieand HS, et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984; 199:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/89\">",
"      Park YJ, Park KJ, Park JG, et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999; 23:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/90\">",
"      Meling GI, Rognum TO, Clausen OP, et al. Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients. Scand J Gastroenterol 1992; 27:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/91\">",
"      Lindmark G, Bergstr&ouml;m R, P&aring;hlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer 1995; 71:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/92\">",
"      Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997; 185:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/93\">",
"      Park IJ, Choi GS, Lim KH, et al. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009; 16:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/94\">",
"      Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 2011; 103:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/95\">",
"      Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/96\">",
"      Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer 1998; 83:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/97\">",
"      Scott NA, Wieand HS, Moertel CG, et al. Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987; 122:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/98\">",
"      Fisher ER, Sass R, Palekar A, et al. Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). Cancer 1989; 64:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/99\">",
"      Blenkinsopp WK, Stewart-Brown S, Blesovsky L, et al. Histopathology reporting in large bowel cancer. J Clin Pathol 1981; 34:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/100\">",
"      Goldstein NS, Hart J. Histologic features associated with lymph node metastasis in stage T1 and superficial T2 rectal adenocarcinomas in abdominoperineal resection specimens. Identifying a subset of patients for whom treatment with adjuvant therapy or completion abdominoperineal resection should be considered after local excision. Am J Clin Pathol 1999; 111:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/101\">",
"      Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/102\">",
"      Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/103\">",
"      Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001; 19:3895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/104\">",
"      Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/105\">",
"      de Haas-Kock DF, Baeten CG, Jager JJ, et al. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 1996; 83:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/106\">",
"      Gosens MJ, Klaassen RA, Tan-Go I, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007; 13:6617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/107\">",
"      Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/108\">",
"      Bernstein TE, Endreseth BH, Romundstad P, et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/109\">",
"      Yasuda K, Adachi Y, Shiraishi N, et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001; 8:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/110\">",
"      Clarke G, Ryan E, O'Keane JC, et al. The detection of cytokeratins in lymph nodes of Duke's B colorectal cancer subjects predicts a poor outcome. Eur J Gastroenterol Hepatol 2000; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/111\">",
"      Tschmelitsch J, Klimstra DS, Cohen AM. Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol 2000; 7:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/112\">",
"      R&ouml;del C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/113\">",
"      Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994; 25:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/114\">",
"      Michelassi F, Ayala JJ, Balestracci T, et al. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma. Ann Surg 1991; 214:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/115\">",
"      Halvorsen TB, Seim E. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol 1989; 42:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/116\">",
"      Ofner D, Riedmann B, Maier H, et al. Standardized staining and analysis of argyrophilic nucleolar organizer region associated proteins (AgNORs) in radically resected colorectal adenocarcinoma--correlation with tumour stage and long-term survival. J Pathol 1995; 175:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/117\">",
"      Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012; 19:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/118\">",
"      Shibata D, Peinado MA, Ionov Y, et al. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994; 6:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/119\">",
"      Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/120\">",
"      Lothe RA, Peltom&auml;ki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53:5849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/121\">",
"      Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/122\">",
"      Sankila R, Aaltonen LA, J&auml;rvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996; 110:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/123\">",
"      Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/124\">",
"      Kohonen-Corish MR, Daniel JJ, Chan C, et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005; 23:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/125\">",
"      Lanza G, Gaf&agrave; R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/126\">",
"      Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13:3831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/127\">",
"      Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/128\">",
"      Risio M, Reato G, di Celle PF, et al. Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer. Cancer Res 1996; 56:5470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/129\">",
"      Gaf&agrave; R, Maestri I, Matteuzzi M, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/130\">",
"      Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001; 158:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/131\">",
"      Kazama Y, Watanabe T, Kanazawa T, et al. Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumor location. Cancer 2005; 103:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/132\">",
"      Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/133\">",
"      Messerini L, Vitelli F, De Vitis LR, et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. J Pathol 1997; 182:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/134\">",
"      R&uuml;schoff J, Dietmaier W, L&uuml;ttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol 1997; 150:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/135\">",
"      Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994; 145:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/136\">",
"      Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/137\">",
"      Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/138\">",
"      Lanza G, Matteuzzi M, Gaf&aacute; R, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/139\">",
"      Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/140\">",
"      Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/141\">",
"      Diep CB, Thorstensen L, Meling GI, et al. Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 2003; 21:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/142\">",
"      Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/143\">",
"      Kato M, Ito Y, Kobayashi S, Isono K. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 1996; 77:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/144\">",
"      Itoh F, Hinoda Y, Ohe M, et al. Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer 1993; 53:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/145\">",
"      Gal R, Sadikov E, Sulkes J, et al. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum 2004; 47:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/146\">",
"      Reymond MA, Dworak O, Remke S, et al. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 1998; 41:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/147\">",
"      Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/148\">",
"      Cohn KH, Ornstein DL, Wang F, et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study. Cancer 1997; 79:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/149\">",
"      Carethers JM, Hawn MT, Greenson JK, et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/150\">",
"      Zauber NP, Wang C, Lee PS, et al. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol 2004; 57:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/151\">",
"      Ogino S, Nosho K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009; 27:4591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/152\">",
"      Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonic cancer. Histopathology 1989; 14:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/153\">",
"      Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012; 19:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/154\">",
"      Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor \"budding\" in patients with colorectal cancer. Dis Colon Rectum 1993; 36:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/155\">",
"      Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009; 27:5131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/156\">",
"      Shirouzu K, Isomoto H, Kakegawa T. Prognostic evaluation of perineural invasion in rectal cancer. Am J Surg 1993; 165:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/157\">",
"      Ueno H, Hase K, Mochizuki H. Criteria for extramural perineural invasion as a prognostic factor in rectal cancer. Br J Surg 2001; 88:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/158\">",
"      Peng J, Sheng W, Huang D, et al. Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. Cancer 2011; 117:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/159\">",
"      Bazan V, Migliavacca M, Zanna I, et al. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol 2002; 128:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/160\">",
"      Salud A, Porcel JM, Raikundalia B, et al. Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer. J Surg Oncol 1999; 72:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/161\">",
"      Witzig TE, Loprinzi CL, Gonchoroff NJ, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991; 68:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/162\">",
"      Dean PA, Vernava AM 3rd. Flow cytometric analysis of DNA content in colorectal carcinoma. Dis Colon Rectum 1992; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/163\">",
"      Karelia NH, Patel DD, Desai NS, et al. Prognostic significance of DNA aneuploidy and p21 ras oncoprotein expression in colorectal cancer and their role in the determination of treatment modalities. Int J Biol Markers 2001; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/164\">",
"      Risques RA, Moreno V, Marcuello E, et al. Redefining the significance of aneuploidy in the prognostic assessment of colorectal cancer. Lab Invest 2001; 81:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/165\">",
"      Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/166\">",
"      Enker WE, Kimmel M, Cibas ES, et al. DNA/RNA content and proliferative fractions of colorectal carcinomas: a five-year prospective study relating flow cytometry to survival. J Natl Cancer Inst 1991; 83:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/167\">",
"      B&ouml;ttger TC, Potratz D, St&ouml;ckle M, et al. Prognostic value of DNA analysis in colorectal carcinoma. Cancer 1993; 72:3579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/168\">",
"      Flyger HL, Larsen JK, Nielsen HJ, Christensen IJ. DNA ploidy in colorectal cancer, heterogeneity within and between tumors and relation to survival. Cytometry 1999; 38:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/169\">",
"      Lanza G, Gaf&agrave; R, Santini A, et al. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer 1998; 82:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/170\">",
"      Purdie CA, Piris J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology 2000; 36:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/171\">",
"      Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993; 14:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/172\">",
"      Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/173\">",
"      Cerottini JP, Caplin S, Saraga E, et al. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998; 175:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/174\">",
"      Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter \"RASCAL\" study. J Natl Cancer Inst 1998; 90:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/175\">",
"      Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/176\">",
"      Clarke GA, Ryan E, Crowe JP, et al. Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. Int J Colorectal Dis 2001; 16:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/177\">",
"      Troungos C, Valavanis C, Kapranos N, Kittas C. K-ras mutation in Greek patients with poorly and moderately differenciated tumours of the lower intestinal tract. Anticancer Res 1997; 17:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/178\">",
"      Esteller M, Gonz&aacute;lez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/179\">",
"      Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/180\">",
"      McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/181\">",
"      Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/182\">",
"      Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 1996; 32A:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/183\">",
"      Deans GT, Heatley M, Anderson N, et al. Jass' classification revisited. J Am Coll Surg 1994; 179:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/184\">",
"      R&uuml;schoff J, Bittinger A, Neumann K, Schmitz-Moormann P. Prognostic significance of nucleolar organizing regions (NORs) in carcinomas of the sigmoid colon and rectum. Pathol Res Pract 1990; 186:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/185\">",
"      Klintrup K, M&auml;kinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/186\">",
"      Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/187\">",
"      Pag&egrave;s F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/188\">",
"      Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/189\">",
"      Prall F, D&uuml;hrkop T, Weirich V, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/190\">",
"      Pag&egrave;s F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/191\">",
"      Lee WS, Park S, Lee WY, et al. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 2010; 116:5188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/192\">",
"      Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/193\">",
"      Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 2012; 147:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/194\">",
"      Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/195\">",
"      Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/196\">",
"      Gaffey MJ, Mills SE, Lack EE. Neuroendocrine carcinoma of the colon and rectum. A clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases. Am J Surg Pathol 1990; 14:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/197\">",
"      de Bru&iuml;ne AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer 1993; 54:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/198\">",
"      Grabowski P, Schindler I, Anagnostopoulos I, et al. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol 2001; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/199\">",
"      Foley EF, Gaffey MJ, Frierson HF Jr. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon. Arch Pathol Lab Med 1998; 122:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/200\">",
"      Adachi Y, Kido A, Mori M, et al. Nuclear DNA content and nucleolar organizer regions in colorectal cancer. J Surg Oncol 1995; 59:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/201\">",
"      Sinicrope FA, Hart J, Hsu HA, et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 1999; 5:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/202\">",
"      Choi HJ, Jung IK, Kim SS, Hong SH. Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. Dis Colon Rectum 1997; 40:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/203\">",
"      Rupa JD, de Bru&iuml;ne AP, Gerbers AJ, et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome. Cancer 2003; 97:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/204\">",
"      Chen HS, Sheen-Chen SM, Lu CC. DNA index and S-phase fraction in curative resection of colorectal adenocarcinoma: analysis of prognosis and current trends. World J Surg 2002; 26:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/205\">",
"      Geido E, Sciutto A, Rubagotti A, et al. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer. Cytometry 2002; 50:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/206\">",
"      Neoptolemos JP, Oates GD, Newbold KM, et al. Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. Br J Surg 1995; 82:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/207\">",
"      Holt PR, Moss SF, Kapetanakis AM, et al. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? Cancer Epidemiol Biomarkers Prev 1997; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/208\">",
"      Bromley M, Rew D, Becciolini A, et al. A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa. Eur J Histochem 1996; 40:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/34/41514/abstract/209\">",
"      Kornprat P, Pollheimer MJ, Lindtner RA, et al. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol 2011; 34:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2484 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41514=[""].join("\n");
var outline_f40_34_41514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gross appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histologic type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Appendix cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other tumors involving the large bowel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATTERNS OF SPREAD AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TNM staging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - In situ cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1641722874\">",
"      - Posttherapy staging for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Protocols for examination of specimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSTIC DETERMINANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Category I factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Local tumor extent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Regional nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mesenteric nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nodal micrometastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vascular invasion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Residual tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Serum CEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Category IIA factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Tumor grade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Circumferential (radial) margin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Tumor regression after neoadjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Category IIB factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Histologic type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Mismatch repair deficiency and tumor infiltrating lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - 18q deletions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Tumor border",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27253668\">",
"      - Perineural invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Category III factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - DNA content",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - All other molecular markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - K-ras and benefit from EGFR-targeted treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Microvessel density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Cell surface molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Peritumoral fibrosis and inflammatory response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Focal neuroendocrine differentiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Proliferative activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Category IV factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Prognostic molecular profiles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2484|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/14/10478\" title=\"diagnostic image 1A\">",
"      Rectal cancer BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/14/8431\" title=\"diagnostic image 1B\">",
"      Annular CA descend colon BE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2484|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/31/42485\" title=\"figure 1\">",
"      colorec CA resection margin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/63/1009\" title=\"figure 2\">",
"      SEER surv adeno rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/54/41824\" title=\"figure 3\">",
"      SEER surv adeno colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2484|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/0/10249\" title=\"picture 1\">",
"      Signet ring carcinoma Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/50/10027\" title=\"table 2\">",
"      WHO classification CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/45/21212\" title=\"table 3\">",
"      Cytokeratin stain pattern CUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/8/25739\" title=\"table 4\">",
"      Contrast append colorect CAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/62/18414\" title=\"table 5\">",
"      TNM stage append CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/46/42731\" title=\"table 6\">",
"      Reg nodes colorec CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/60/8139\" title=\"table 7\">",
"      CRC tumor regression grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/34/33323\" title=\"table 8\">",
"      Number LN survival CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/41/19099\" title=\"table 9\">",
"      Survival by LN ratio INT 0089",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=related_link\">",
"      Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_34_41515="Donor infections limit lung tx";
var content_f40_34_41515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Donor infections limiting transplant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Donors should not be used routinely upon evidence of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gram-negative bacteremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterial infections of the chest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Invasive fungal diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis B surface antigen-positivity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV/AIDS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Creutzfeldt-Jakob disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       West Nile virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe acute respiratory syndrome (SARS)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Donors may be used with caution upon evidence of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gram-positive bacteremia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterial infections outside the chest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fungal airway colonization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis B core antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Herpesviruses (HHV 6-8, simplex, varicella)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cytomegalovirus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epstein-Barr virus (high risk if donor",
"       <sup>",
"        +",
"       </sup>",
"       /recipient",
"       <sup>",
"        -",
"       </sup>",
"       )",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; HHV: human herpes virus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Garrity, ER, Jr., Boettcher, H, Gabbay, E. Donor infection: an opinion on lung donor utilization. J Heart Lung Transplant 2005; 24:791. Copyright &copy; 2005 The International Society for Heart and Lung Transplantation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41515=[""].join("\n");
var outline_f40_34_41515=null;
var title_f40_34_41516="Dx criteria atopic dermatitis";
var content_f40_34_41516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis affecting flexural surfaces in adults and the face and extensors in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic or relapsing dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Personal or family history of cutaneous or respiratory atopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Features of the so-called \"atopic facies\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Facial pallor or erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypopigmented patches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infraorbital darkening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infraorbital folds or wrinkles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cheilitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Recurrent conjunctivitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anterior neck folds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Triggers of atopic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Emotional factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Environmental factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Skin irritants such as wool, solvents and sweat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Complications of atopic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Susceptibility to cutaneous viral and bacterial infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Impaired cell-mediated immunity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immediate skin-test reactivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raised serum IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Keratoconus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anterior subcapsular cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Early age of onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dry skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ichthyosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperlinear palms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Keratosis pilaris (plugged hair follicles of proximal extremities)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hand and foot dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nipple eczema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        White dermatographism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perifollicular accentuation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnosis requires the presence of at least three major and three minor criteria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hanifin JM, Rajka G, Acta Dermatol Venereol 1980; 92(Suppl):44.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41516=[""].join("\n");
var outline_f40_34_41516=null;
var title_f40_34_41517="Cabazitaxel and prednisone for prostate cancer";
var content_f40_34_41517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cabazitaxel and prednisone for metastatic, castration-resistant prostate cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cabazitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline or 5 percent dextrose in water* and administer over one hour; special equipment and preparation techniques needed",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prednisone",
"        </strong>",
"       </td>",
"       <td>",
"        10 mg orally",
"       </td>",
"       <td>",
"        Daily.",
"       </td>",
"       <td>",
"        Days 1 to 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        &nbsp;MODERATE (&gt;30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Intravenous premedication with a corticosteroid (dexamethasone 8 mg or equivalent), an H1 receptor antagonist (diphenhydramine 25 mg or an equivalent), and an H2 receptor antagonist (ranitidine 50 mg IV or equivalent) at least 30 minutes prior to cabazitaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         &bull;",
"         <strong>",
"          Infection prophylaxis:",
"         </strong>",
"         Primary prophylaxis with G-CSF is not justified (risk of febrile neutropenia 8 percent",
"         <sup>",
"          [1]",
"         </sup>",
"         ). However, bone marrow suppression is prominent with this agent, and deaths due to neutropenia are reported. Consider primary prophylaxis for age &gt;65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation, poor nutritional status, or other serious comorbidities. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Cabazitaxel is not recommended for patients with bilirubin &ge;ULN, or if AST and/or ALT are &ge;1.5&nbsp;times ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . Cabazitaxel should be used with caution in patients with a creatinine clearance &lt;30 mL/min. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\").",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential weekly during the first cycle and at the start of each subsequent treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Renal and liver function testing at least every three weeks during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor neurologic function and gastrointestinal toxicities prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Do not give if neutrophil count &le;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        . For prolonged grade 3 or 4 neutropenia (greater than one week) despite appropriate medication including G-CSF for febrile neutropenia, delay treatment until improvement/resolution and neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , then reduce dose to 20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . Use G-CSF for secondary prophylaxis",
"        <sup>",
"         [2]",
"        </sup>",
"        . Discontinue cabazitaxel if these toxicities recurat the lower dose level.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        For grade 3 or higher diarrhea or persisting diarrhea despite appropriate medication and fluid and electrolyte replacement, delay treatment until improvement or resolution, then reduce dose to 20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . For persistent diarrhea despite dose reduction, discontinue cabazitaxel therapy",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent,&nbsp;cabazitaxel dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte colony-stimulating factor; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CBC: complete blood count.",
"     <br>",
"      * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"      <br>",
"       &Delta; Do not use PVC infusion containers or polyurethane infusion sets for preparation or administration. The manufacturer requires that two dilutions are performed prior to administration. Cabazitaxel can be administered in normal saline or 5 percent dextrose in water at concentrations between 0.10 mg/mL and 0.26 mg/mL. Use an in-line filter of 0.22 micrometer nominal pore size during administration",
"       <sup>",
"        [2]",
"       </sup>",
"       .",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        de Bono JS, et al. Lancet 2010; 376:1147.",
"       </li>",
"       <li>",
"        Jevtana (cabazitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 13, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41517=[""].join("\n");
var outline_f40_34_41517=null;
var title_f40_34_41518="Effect of CPAP on CSA associated with HF";
var content_f40_34_41518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Effect of CPAP therapy on heart transplant-free survival in patients who have central sleep apnea associated with heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 522px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival plots demonstrating that compared with the control group, the CPAP-CSA-suppressed group had significantly improved heart transplant-free survival (* unadjusted p = 0.043), whereas the CPAP-CSA-unsuppressed group did not (unadjusted p = 0.260).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: A post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial (CANPAP). Circulation 2007; 115:3173. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41518=[""].join("\n");
var outline_f40_34_41518=null;
var title_f40_34_41519="Bogota bag for managing open abdomen";
var content_f40_34_41519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bogota bag for managing open abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 281px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEZAU4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCl4n0K81DTpLTdhT0OK89/4Q+801vulwO+K6iP4hQkgu/B7GtjT/F+nag21tjDvQB5NqtrJETuUrx3rJ0e+Sx1MNcBijHBUHGa95udG0zV4iY9mSOmK848W+AJoN0tjkkc7T6UAZemahFJJKjkIN2VDHsa3EuY2jCqQfcV5y4eBzBeI0cqjhu9Qg3UeTDcMV7fNigDudXV5bOVYWIYg4xXnYEyXDLMpDE4JYYrRi1K/iwTKeB3Oajupnu8vOwPHpQAyJGgllYOGDHAK960fF1n9mttObByUyfrWZbXSPeRBwBEhz9a7rU5LTUdNhLxpIEXHXpQB5sJuCCBg+1dt4bcjwhfDOSOfSqBstLc/c2kdcGtS2FvFpktpbSBRL13UAcBLIzn5jkVHWlqmlvZXGxWEoIzuUVUa0nUgGJwT0BHWgCHHNbVkXXQLgqf4xVWDSLyVseUy+5rqNI0lILR4bkM4Y7iFoA4l3diN7Ekcc005zWxc6RJNfmOyX5WbC7jikOgX0dzJDIgBTqc5FAGSpwc102o3Bh0qykj64pLHw/bMokurnbzyoFa2pw6bJZLEZARGPlANAHP2PiC/sTvtLh0k6kqxFQ6pqOpazcia6aWaTpk5NadvJplrAo2K79cnmoptdjQEQRr+AoAn0KCSLTrtZl2eYpAqbSfAt5qOjXuoxvhLcE4x1rEm1qeVSM7fpUkHiXUreymtLe5kSCYYdQ2AaAKz20NpMpkYsynJHapdZ1mbUjF5gAWJdigDoKzZJWkbJpjH5hmgDU019oBOABzxXVeGj+7djgbjkVwsMhQ4BwpPNb2m6slum3dwKAO6yACWOBVWS+tk5aZfzrmtQ8Ro9oyRE+Z6iuWe5kdizM2T15oA9TimiuEJjcMK5XxHFCsm5VAPeqWja0bWAhvmPTmoNTvvthZ0oAhjIY/dwPWp2xswaggU4Xd6VZwBxj8TQAwqcjAH5Uuxs8mpsHtQYztB68UANKYIIbPtSMAMnAwfanbCBnPvUbEYwemPWgBm0selHl7c4/I1GsrAkbRtHQ5608yNjgHmgCWJmjJIB59abJIrtnAzUSq7ZGcD65prR4c85FADBcMSAWOM+tbnh9piWeEtkDnBrnGU7RW74ZujDMdh69c0AdvpniCazYeYzjHXmu50fxHBfRCO4O7PQ15/PbpcwebGOcZNVbNZYW3wydD92gDtvGHhO11aB5IFHmYJDCvF9a0i70mZo5QdvZvWvZ/DevmNgl0Tg8EGpfGen2OoWPmYUySH5AB3oA8DiBKiRyQg/WormYyMMcL2FbnibTZ9Pm8p12qOnaueORg+tAArlen51pafqsluSHy0Z7Z6VmEYFHWgDQuL4O+6IYzzikjv3THJqgBkjHWlKkYzQB0tpqlrIyfaE+cfrXVeKvEelXGn2bWcEf2iJApAWvORZSi3Ew6E8Cu5+EumW2oa7JHeIJB5TEBhnnFAGBD4iIbLoPpitKHxRboCJIz07VzOsW/k6rdRoMKsjBR+NQi2JtzNkYHGKAN59ehVy0MY3HnNVb7xBcXBb+EnuKwxyeMU+VVUD1780ASSXc7jG9gPTNQ+a5+8zEH3pQpIJpcnYFOMUARtuwOoFWraCCRR5kjAnsBUcUe7sSK6bw34fivPmuJ/LXPAHWgCjd6GsenrdQyblPY1hbcknsK9X1PSIodF8qAkgA815pNbmKd1PKj1oApd+tIcZpXPPvSUAJnPWjNFHSgAzQKKMUALnqKs2rZG3ODVbPGKsW7AYG36mgC+gAwetTjB6gYqtEOnOcip1PQZwKAJlbAHalyxzsFMQqqHdzg1Irhl4GKAImV2zk4HpUYTDHd06AVZK/LmoiO9ADNg7KB2oYA5HP4UjFs03nkbjQApwOR1PpTSGbpSgc9aemMYzyKAL1roE32cz3OFG3hf61maWjLf7Iyc56V6TfqRZvuFcR4dUL4mUMoILYoA6fR7goQkhOOhBqTU7YwTb0yFarGu2X2S5WeJcRseasyslxp2HI3JwKAMe3vWViH5I710Wi6kqSrLP8AvAowoboPes7SNAk1G2uJIHUSoMgHvWS3m21wY5QVZTyKAOw1XQU121e4lGd+SPavL9T8J38E7iCMyKvTHJxXrfhXVkaNYX5BGK1NSsXt2a4iUFCKAPm24gkgkZJVKsOCD2pqDuDgd81u+Lgx1q4ZlA3MTtrFA+YA8Y9RQA5Y+SQc45GKmSIlecZxRCMqBk59qsIOMdxQBq2qh9MKYHHOaboN/daTfrc2LbZACPrUtiCLSTg46U2wUfaRuAx6UAS2ug3OtzT3RcJliSc9Seauz+CdRj0ue4hCtbxcuc1t6LcvDCyQW5dc8kCugh1GabTrq0+yy4lU9DxQB4fcW7xuUOBj0700wkngZAHNdq3hTUdQ1IR29lcSgkZ8pSfyrtIPgd4pu5EOnaTMtswGHu3VDnv1NAHjBjkB+VTtFH2ZzyO3qK+gbH9njxLJcrBeXml28rjIUzFzj8BXRW/7MOpbR5+v2Qb0ELGgD5jt7dycoWB9CK17T7XAwIOQPSvov/hmO+Vsr4hsx/27Nz+tJ/wzfrKZC61pzDsTG4NAHhr6zdi1aJueMYrm7lHmlJI+brX0jL+zr4g2HbqOnMcgAAsM+p6VTk/Zx8SC5CJeacYv+em9sfligD5tktH3HA3EjGOuKha0dB84I+or6J1L9nvxfFcKttFYXA/56LOAB/31g1m6l+z545ihDpbWlwe6xXK5H54oA8EMLA89BTdmTgZr1DVfg/420+3kluPD155aAlnUB+Pwrk5PC2pxkh7G6THXMTCgDm/KbOMGjYc89vWtt9HuV4eORQPUEZqF9NYH5uvvQBlbOantlOflz171aNjgdajihZCcZ9OaAJ4EbPQDHepShbGenYUkWen8qsxLz/jQAgjCj5uRT1Hy/KOfWn4AX5gM0A4B9aAE/hwfyqJ25wMYqXBKj65pxTGDjmgCqIyQMdOtDQ5TjqBU+wnnGB7UrR/yoAzhvU/MOM0pC7iOT+NXGTAPGQec1V2nceBQB6jqCr9hcAdB1rzzST5fiOLJH3+v5V6TcqGs5BivMmb7PrPnfxI2RQB63q8CS6Y3mMBgcZrndESKSYGfLKOgrV02ZtcMQcYijGWHqaoXVubbVmVchCcjFAF7Sr/+zdTcAAIwxiqXiUW1wj3MbfvgcnAq1qlskbwyrjDYratvC0FxCk0kh2uMkA0AcJo94UkDKxHSvUPDuqLeWv2eY5JGOa4nxH4ej0edJLXJjbrk9KNOu2heORDjB5IoAk+Ivhbzc3FuuG7+9eVz6ZNGxBUn619F20iarp5WQ5fFcPq2nRW91IsijqaAPKY4JFB3Lj2qdQ3pxjrXodv4dutSz/ZumSz/AO1jCj8TVnT/AAi6GQ6hJbwNG214yfmU0AcnY6fcPaYRCd54A61saP4U1We8TyUjQk4/eSAAV6j4esdLt7Xb5Re6j5+Rh849QKr3PyxtLLiJg20BuuOvSgBnhHwJdT6m1rJIrtna3k4IJ9m6V6augaf4SG5tP8+UgEyStkDJx0+tc14cfVY7mzGklbJZeCAwK4HsT1967y7tbm8eBtSuLsyoDiRiUA/FQRQBhX3jSeCP/iUWpBYDlVCDac8gH6eldJomtavdPZQPJZqskbSs7HzQfQA9j61LdaMrRb7iyEkaoArsn3l9AQev4Umm6ZptlA7vZiKwmJkG8/NkdcYwaANPwprMrxXAls4oWjdy0wztZAeME8n3rp31W3jSIu24uP4OcHjivN7jU9Os7tVhuJ5Y3G1RI24gHt/Kkmjs5JD9nn2QZ+ZFPK/jQB6nHdROPvqDnGCaILqKeSRI23GM4bjpXncrQXGnFbTck0YJSVua1NFs7jUtOSG7upAmwKCqlCT7nrQB1X9owG7a3QhpF5bkAAf5NTR3Mbu4DKVABzn1rz3Ufh/ZxTxPFHuJZWY7iu7AxgkYPP1p1vcT6HqLWVrYxCzbllj3MoHpknjv+dAHa6fqQvLy4hRPliJXf70y6nb96MHy84yD2rgr7xbe6Z9pe1sgbSFNpl4BJ7Aj2rQ8OeLEayWW6LnzR5hYqdvP0oA17pzeOYPtDRAjc2Dzj09qpgNbuRBc+eBlTuOaZfaxpZZFjUM02WMcowSPUMOlMnudKUyuZ7myeNRGrGEsnTtxzQBYWS0urab/AEO0naM4cShc574BFYniv4U+BtWtlnvdOFlPNt/f2rlDn6cr+lVvDtlB4mjmvIdWH2oSOikw7A2OAR+FX9c0bX76xt7ZLmzka1b51VyrcdOooA8Z8Zfs8axDMX8L3kGo2jLuPmuInU56dcHjvkV4prHhPWdIu5ob7TrqFom2ufLJXP8AvDg19qx6drWl3VtNPIZYGIVvKO48+1LrF1by3kdrdttVFy28ED/CgD4VEEsTbXUq3cEYqZF4/lX2jqnhnw74ojcT6dYXiKMb1AV1+hFeV+LfgpaeT5vh+5lik3AGK6O5f++gM5/D8aAPBCD2pFX5gSK6HxD4V1bQJdmpWckaZwsgGUc+zDg1h7WB6CgBnBOCMc044z2pCp6Y5oYYxkdaAEHBPvRt60oBIp23PJ5oAjCYGO1RNGCfvYFXAvGSKaVy2ccUAegTqBaPk8EV5lextJrAVe57V6XPBvtCpbjFcFcJ9n1NnPIXigDpdFuJtIvkimB2Sr8tbWpQTP5V24+RzxWJdy+dNYSsOAQOBXomrW6v4XRlA+Q5zQBz96vmaTFJ6ZFdN4aM1xoyOkZITisC0ikudN8qJWeTsoGTXReHI7/TdOaCeFkye3Jxzk0AN8Q6c99pjAbdwXdya4bTNKubgOgUIinaXc4ANd/c3MYCtHMHUAhhwc1gXoe+LtIWiiUDJQjp6HtQAumT2WkWRUmS7vz90LnYB7YpmmaxLZ3Qb+zjIgbeQ4JLc55PU/nR4d1C2tw42sDGeD2Pua121KW6LR2jhI34O4bS30oAZaXt7f3ty8Lpag8suOM+g7Cqdnp5n1KU3h3RRnYxcdSfTGfzqwlnNbeakBjWUZDc9R9D1+tP0+1ulmDRhiXb5vL9O/FAG9puh2Iumlt7ZUgUfOxZn57AY9fpWv4o07SF0cS2sTW820MRnf8AqKsaNcCGYpEijyhwyfI2cdcHgmrmqaLdTWPn25V/OJzvOxxn2HFAGB4F8ya52GbEg+6doYfj3r2QaNbm2SO3uJY5MZYo3U+uK8U0s3Wk37rAuJFb5w645HXkV6xoWo3F5bBp4khPH3GzkUAdXb+dBGvmuXCjALDk/lWXrsUeopDayyiIu+1eO59quWt55vDtzjCg1j6ppEdzqK6jFOyXCYIBPHHbFAHGa94d+yyNdSNH5UX7tQhwZOTz+P8ASooLFBZeW+Nu7cQG5z9avahplzePJdXDhIo2/dpnAJzznPX0rD1G1YWwKMxcHd8vIFAF63LCZVgdkTPrnj3rutMmvbO2hnAEluxzjPzH6V5bo73NwDJApJGRzxivRdGlCWMc8rKsqKqIvrQBum/kmt3Ron8x8YAHFZl5pc6RSme4MTMhYKBn8PrVq01qGydfthC+a20bRk596TxHqdtJaeZBIruzBIsHqT/SgDg9UQ+SYLY7zF88m/oW/wAip7a2kt9EhmXBAXaysAMn2rq9O0+GewjgDiQ9ZHHf1yaXWoLSTSHtoBl06EdqAPNLy2FrOJHc7pHLDPQKf6Z7VvaNevf6nbo4DwRJnaTwTWJ4iguZ/IhVQyrx/u1d0uyuNP1AbNhZUyApBDcdB70AdzpdhDFabIo1iJcsAo6Cm3lrJ5UkYc4P8R6isVNdEV1EqMFlI+ZG4wa1ZNS80ZdtzEY+U0Acndard6e5tpZZCikNG4JwMHrWjeeItSN7bXN3DbOTF8hXJVh7j/69VtYtGktzuHyMCVJ65rlJLm8gubeG4y0CptB59aAOytFgE8kstlb28EuCXtXZXj9/cZ7Ulvdfa7d4rfU0Fyp2MlxDgHHTkH+lY2m6jBJbMsxYFfbtUREUyQTPHHMobb5jD5vbmgDfv9B1K90xXsRZ3M2CJoGYFH9VAIrybxH8IZ7yFrzS7drWZgWMBO6PuTjuv45r0Qajd2EivaXEjInIRj05rN0jxPetrIN1hN0uVGCMNx81AHzhrGkXmkXkltf27QyKcYPQ+4NUGU554FfXfxA8Nx+KdAju2sc3bP8AvVxgMBwWHowrkLv4CWl1pCz6Nf3f2p1DKtwo8vPoSOR9aAPnD1pwPHFauv6TdaNqt1p+oQtDdW7mN1b19vUHr71mkBQR3zQA7bgAZyaMEDikBAwKlGMc0AdBb+JLCWH77ISOQwxXGaxepNefuiNpaqDxSZBKnPQ5FReWwkIJOfagD0eKNTo1rLxksP516VIofwlJ8pOErw221m5W2gtpMGKM54716foniSG88N3cckgV/uohxkDH+NAG14L1Kx0+yna7R/OdgFYDIAp/iHxLZXJeC3eQSIvDAYAOfXvxmuSguY4LMtKXwemwZ59/asC6vrq+vxczMFVx8hC4GBx0FAHZWQWcLHG+C53O/TPpXSm1ht9OeNgNpXn3rg9Oklktz5C5TILADrXSXFxImnojuTIVyQf5UAZtoFWadlTYqZ8tMdSf51sWmZwisQvlfKAF4z/u9ag0ry5E8ucBs9c1rrpakrJCy4xxG3QfQjmgC3NZzmCRpcBQinLjK+4A6ip/DqBLhi+8QiM42ndyenuKZHc3dgkYmdpS4ysY+YD6sP61r+HTp94Xu7z91MrhFYnaPc5FAFjTp98W28jVwx5eM5Ax3I6itmyjtyQdKvXIQh5Iyd34Y7Vhn/RddeRJldJULKMDGc9zXT6MEEDl4ljkdsg46gD1oAw9diuwrTSWqCTPLwn72fUVo+HtQa1sWa4G1oxxuPB961NRs5RZyOz/ADcYdfT+tcwPJupVjkjIYMCc8gkelAHVr4otWCCSNlYjkr82DnB6c1qfa1njj8k/I3PpXLv4f0+UBgJYxGwJTdkN7ZNb1o0O0s0jxtjA+XOBQAzXbjZYsBHvGM4zjFefW93J5z+bIoTnCt0PpXdaqFktZds6spHCtxzivMLrT7iZpI4xxuwDntmgDrNOkSztw+Y3LDJ2HIq0fEMkUQSJPKXBDNgHcDWBpWh3pCATbY8dN1WL7TXggxK45PO4UAW7LUPPuFuZC0qRMMg8Z56Vq3DPc6jH+7XY7ZAXhY9xyR/SsbRoI7a3APKn5q2IZAJIp8CFV2ggNnfzyefrQB1cUX2XTSsbqmQc4rPtJHlka3WUYI5zWd4jlZrB7eOQLtG4NnrVPTZ9lujRkNMww2D0NAGu9rHNNKikllwNvY+tcp4hnl068ibYQT1I6Y9MetdRp2qGzllCENIy7WJAwPcVDdGx1G685QFKnHXv9KAOMv2N54gZRdW7uoGXXIU5AOPqO/vXRaZvji8v5G2HnPb3qvfaNY289zf+dCXjO1YQ3LFu+Pbvisr7RG5Kx7oJOnHI/CgDb1EJHNKskyfKuRGD9455xVLUEaNISFBC9QRyKpXRmaIJII5SMfN7VLeaiZIVgHMgPzOxzkdhQA/T7eC7Ry0UivtI3JxVGwgureOaIS77cNuA7itKynkit3QMqMx5U1LCi5DI2XY/lQBkSyyIxEg+U9c9aqXWx3ied+h+U46HsfpWprDq2Q4VhkfN61y+sy/Y7WTYMxkHBPOKAOx8Ia/9k+2WF1IRlsr82VBPp7c10sHjG20WGK1mjmklhXc4iw45PXg9MmvI/Bn2e7sJZbrDy7/uk4I9CKi1LUFIk06EEbGMwbvgdVP86AO48beErD4keVqUxj0yePKmUgbpQSANw9vU14N8RfA+oeCdXFnegSQyrvgnUfLIO/4ivZvDm/VtGje2kIltm2TxqeXjI4P4c1J8Y9Fv9Y+G9tcSiMS6bicMDuMin5Tj0PQmgD5nCkEVIuSOoFREnJ/Snx55zyfegC3JbRuDtZeRVePTYyeRk1Xtbdg/zyOgHsa04URThZGcn0FAFKSwVTjAqJoSnRunpWyYhydsn1201rPegY9fpigCtHq1xDpptFkyp/iPUj0rorL7PqGjQbnxcQjoBwfQVyupW8dvCrFxuzWpoLoYBg53elAHTabMsLEKu1Rxg96XVtSjsYXklYkBsKvvUlgkTWkokBaRvuN6GuU13UrYXP2e6h37R97P3TQBuWWqRBlc3Cgt0BPNdzpV8kyKEblccV5Hb6EL1Fk067VpMZC55+lWLDV9T0eQfa4ZXj3bSSPT3oA96t8NDls7vpWjpmiNd6czxAxSStnIOFAH94dOa4Hw/wCLLG5tUmaXyl3bT5pAyfb1r0DStdWGwe0BLwTZBaM5KZFAFVvCtzbRiYTQztksfKcjOfY8Vp+Fb6/W6Swvol2s3G9Sj49u1ULaa6tlxb3Lsq8hX+YfSum0fxHAZRHeR+VJjIY8j8DQBL4omfTdJm/1k0D/ACqFHzIff2rzK31a6tHBy0kfbcK9a1d4r+1AgcMp5O3GGrmV0+xRGSeycY5LHnmgC/okz3NtGWGx+rc9c1avH+bIcj1wcVizxzx4eFzt9V5wPwrPF95KNEzFzkksSaAL+r3mLcBWGM9c9qzPtcBXETrgEYA6/jVC9lE8eRJ5fGDgE/pWfaiJJyonJfp9zrQB6foEQMUckvKY6VF4g+zTPiQDylrM07UDFZKIn+YDoaqTtc3uq2sEJ3lnBI9aANFIVUqwAEZxj1xWR4ha5uY3t7FlUpllGeTXYPZHdhQEkQHhvWuck02eDVTcKyP0ynTPvQBy41e4S28i63NMeDIewHapdN1CW1EkhwxY8lj/ACrpkgsZbiWKaCESFtwLd81auvD1lPbK1tGquvVVbHNAGANT3SbUUquOWq9p8lvJJueXaqtxnoTVB9HuLSCXZulU89OgzUM2FVRFyS2H9BQBsXVoJJjKrIdx5B5I+lPTT43BRlBGfu1iT3Yt5Y4t7B85yOlanmusZy4yVz5nTFACT6b9nJ8iXcmPutzt+hrI1C6tWVFuQYLpTy4GFPvV6a9jkJUTjI7k4rl9bjnug0cI8zByCByKANZ5ryWACLEn+2nO6ks7xmmCbzHOn8LcVy+nT63pKkLbTyQtzs2n8609SMtxarcTRvbSHkkrQBsX2TCpmGWzzjoao3lik8BQ5MTj7p6iqsd7LFpo3MJdpyGBqQX322Im3Uk4+6vOKAMeeA6Wkf2N9wUksM81Wvr5VnF4oAdoWVjjPUYpb6K8e4ZjbXIkU8naQDUV7p8j6OZpl8kLztYYz7UAaPhbV5tMlW5g4KtwOzjup9q9UbXhqGmW11auH04nD20gDGFsYIPqPT614fpsN5JYFkKJHkkMx/lXefDW1mk0rVVeRJZdwIjRsjAHX+lAHjfxC0KXQvEN2BDtsZJWa3cH5Sp5wPp/SuYVwfWvdPibFFe+GbzzkxJCuR7MP8mvBFbrQB2iqinDqGz7c0ySxtpcMF2MPTjNSn5R8ucmoJJXUEkZoAGuBbDaoyMdDyKybnUoAxDqFzxxT7iZ3JAFZk0a7t7IC3vQBU1W4SWVX24QcDjrTtG1DyZyFPyg8CiaMSqQ3cce1ZaL5Mwx1U8+9AHq2m3AuoI+cd+tc5KLe8aUXtsubiYxxsB82RxmmaPdfu4zG+0gZxmtGZLfUmjWceRIhyjqcYz3/OgDK0vQrlQz6bdKbiJ8AA7T7V1NvqF7ZWEUGpWxuZZQ0jI+MiMHBJ9TzS6Vp6aVd7A5Yy/NknkkV0E9pZaoipdojsoIDdGUfUUAcvLZ6XrUIOn3kFh5aYWCYbVJJyTn8hU/h7+19C1q23Rym2lyZPKOYiSMAgj0961bvwdZS/LBI0MRYHCjIAA5Bz6kk5qhd2Gr6fZ+XYtJNFE4hRo+dxbJDYPqSB7c0AenWmqrKgY4J7+9TXlyZLV3t0DPtwFJ4rzrw1qd7O0v2qFoRG2w5UjJ+ldvpV7byfu3lUNnoeDmgDKju9Zs/wDVyTwwjgYHy/rWsNe1iwZDIQ4Ycrggiuxs4rVrQFgpXHU8is7VlR5BKFXDdNoyPSgDa8Ma/pOqxrGStrcOCDuwCT6daZqFjdWEz+dAJ7Zjw6j3rzTVIktbuT7EckjcQpxtNaOleM9TtYPKkl89Bxsl5wPrQBtXyoLggAqCfut2FZk/7m5UpGAR0xWvp/jDTJ5St9YtHJ3wNwIpZtf0qTC2Fqu3OQ7UAVftcgiHmWzNxjIGOfWr/hdLuaWa7WB1KOoBXnr0xVa6hubmePZKGjlxtKjKnn0rt/A1rc/bEaaWJbcEzeWqdSPkU/oxoAurZXyyvKYZpVYYOVx+JqG4to1lUyhgcgbRXfqoAwBxUFxaxSDPlpu65280AeZaz4XWedpYNyyMuQVzzXN6xZa3YWpmtpZHVSMhRyPwr0zVW8qMR+Ywljzs3nGfb3rj76/MlnItq4SduSc7v0oAp+Ari7ulnu70tN5ZGEdtigc5z61neKoL2C9WW0hU7uQkZ3Fq09Cjm8plK7JJX5dRyQPUdBS6/qtxoMqslkJcjC3Bf5Qe+aAMe10bVtTKy3WLKMEZ80Hcfwro28MRRxKbq7mmYj7i8Z/CsrSfGBv32XQgTGW3F8gVrLqaGRZI5QFYcO3egCsdJtbVGAhRMc5YZJ/GpLaa3hOMRoemFWpL/VdPjtZJLi4h2qOWIPH51wus+L9Ihkb7PMZGXoEHDUAdrJescKWUr24qrepAy/6Rzu4IxxXmEnxDjaRCIwoB5G4Yq1/wseCUGOGBpHxlRxjPv7UAdDLYWqmWO3tdyY6KOtR+G7ae0ScRRG2UMdpcfM3pmsDT/Fdzc3JZtq7R90c5rUOvmGWJrklQeSPX2oA2Wa9jdzJIZmPUHgCuV8Vtd3zxJLEsdtnGBW2PGGmqJcY83GAG5rB1HV1unDQXUbMOSpHX2FAE1nptuLRYyDIm3ox6VTtdcTwrqn2m0Z4kKlHVe696mtdRiihL3Eqggc9q878b6/DeGcWiAN/e9fpQBq/EHxrFrCPDZIyeY2XYnqPp615wMgnFUUmIc7iTz3q5FOHyRQB3smOgqCRSeDUrKd2etI3XGMsaAMyeHDHAJz1qlPCQOVNbpTn5qQ2+5CcGgDlpouDxjAqk8KShuCHA4Ireu4tucgVkvEBIATjnrQA3SzdSSJbRxF5FBPy8HArUivcMCwzj17fUVFDuQiaI7Jk5BB6Go7iZ768LzyJC4Qlm28M3bigDqJ9RaSG2mjHzoM7q6LTLvzlV2COD6eleaWN+bdyrgGM9R2Fblrfm1mEkMn7h+cjtQB6hbSRMEcKqt0A3Vrac5MxyEYN/CeDkdORXF6ZqMkio0e2ZccMv9RW/p9/BJKC5Mcw6DpQBtapZoxD7QOckHrXNw2F0kjrGwYsd3T1rotV1FI7RA/zmTO09xiuas9YAugxOMEjGaAOt8Ni5ht5DOMAHaEJ6+9WdemmiskNv83UNtP3TxjNVNOvQXUKy8nnNaFxLH5MoWLcSVY8+h70AcLFdmO6dSVMjcsQO9JEQ0rEoPQYrpNS0yxN0rgA/xYAxinJa2rwyKIlLbchhwaAOOuvMUs8HmLNjbkdhWtoGmXkkCu+SpPQLipLO2aS6w3XgYz716dYafDDZI/AwvII70AZllJbJKImQ7AMLnjbXb6WIXsZW0x49zMBhWyMqMAZ9eM/jXl+v34umESoAkTEkg45xU+l+IJPDpto5os2crcvnlfegD1WTxVHHPHG6GN1O2UE/xV0NndCdOoyRuXnqDXl6MNeuYr7SmWeFziULz+dekWVp5SQthgUQfp2oAx/Ej28jReeAvUZz0NeR6oJUuryKG5ClJCApO3ivZNV0lbx48jgEsR614V4/iZPF15bp8vIA59qAOh8Mr9mtv9IvY0jJJIU5Y/jWP4g1N5pTHD509qjfMu77+D3P4Vz2kXo0rUVa6RZwDgg9BW14k1W2SEnT3RpJl5CjAWgDClvFs42l82OCRucbQ2R6VD/wnM8MLJDbO8nZmAAH4VzCrNf3xjAMjA9SfSui0DSGN8r3EYZE52k8UAVUi1fxJOftkzpGOQpHH5Ulx4QuDJt89ljI6lOtep2s0UMfyQRcDjjmsXWtTU7xHu3devAoA8yTwxbwXGLt9wwe+KsW2kwWnnSxIXDqUXy2yQDV3VJXdg7sDnrjpWZbOyXC+VIVOcYFAF/R7GK2i+0SyneRhVx0xUOq3xkuEO7cQMHsCfWuyiRBAgaNGZl5Awap6hotpPbSTlRG6qTtxQBwt5OZG+XBJHPNLZiNSpkGJO2KxdTuDa3bpwoB9azJNUJm4kIz3oA0tcuS7uI5CAp5Fc2ubiYqM7R1qfUpglvhSST1JPNYazsBjOPpQB0kdpYIQLl1wT83rUgv9GhJSLS1kVTjczkk+9ckZmZSS3INO3M65JINAHqyqCAR0psgweetWY4dox/KmyRF2GKAK23PUdanVMRAZp/l4bP4VKOBwKAMe+thy2KwLyHbu4zzXZyxhwRjORWNf2hKnI+lAGHb5OAadLCrM27GfTFSKDG2COavRRrKowBnvmgDCaABwGbCHgj0rRggSGDfaTLcR8h0Iwy88fWrEluqN+8GffNVntMuXhLKR6d6AJtJ1b7DMTHu8onlf7tdnpmrQX6AebnPVWA4rzh0lF3wFBPOTxmnm4ktJI2b92WG5Sp4IoA9nu5YJ9PxMxyi4Ug4rkZmCSDDZGc81iW/iCaWHZKAwwM+9KL5Zhj7rDmgDt9C1hF+8x3DIxXXpdwz22Q5DkYz1wc14/Z3qI2XwBXQaVejzBtlYK3UZoA7p5lLDc3Q8/jTI5lXeQ2MCubku5IhgHchPrStMcglj06ZoA1LKZRqkT9QHwQe4Nei3epqulSnGNicD1ryAag0FwJC+V9DXc6dqlrdWG6WQcj7p9KAMtLhI5YvMPDH5s881o66sOq2yxfdeIELj3rhNbuXbUpvszfuhjaaZbeIZbdyCSxfAJPtQB1vgLxLL4Y8QSW1w3+iykBsnofWvovTdUhvbRJYWBVlyMGvke5uIryRWlbDE9q6nwp4vufDt5DCsk1zYOdojJyV+lAH0amoRmWdc4aPGSfevnXx2lwfGN3Pu+QvuBNervrdreWySpgTmPLITg89jXAeKreK5n/cZMh7ZyBQBwF2ZzcEoDKxPQVl3V5LllyFx1Fdzo2iz3dzIhcRjoxHGKw/GXhqTSf38Z3xN1IOaAJPh7aWl1cztcuTIANqgdfWu+W2iEbrCqRt2IrxfStRewvkkjkKDOGOe1elG/8APCNBJ8pXJbNAFq6kaEkM34jisu/i8+Msrse2BWfqmtRQPsJDOenOau6NcJ9j3zsxlb+FhgCgDJuNLaGBpbiTEQ561y8lwj3gWLlQ3Hauk1xXvXZGm/cg8Kp61zr2YtpsJye2aAOySV47SJowF+XnPaqtzqbmB0dxyMcVALhRp6eYyhscgHpWFdXcUSvJk7AM8mgDgvEDM2pzqGc84BNNtrUKomnB2gZGe9WGkjub6WVgFXOcms7V9TMx8qP7o4AFAFXUZxLKwU8YzVNzkA9DUkMRYEsctjrUUiMkh3cjigAwCOvNPjUEnJxUa8nKnrUqHsFGQOvrQB7IRySBSqPlB6VcMIHGaUIAc4ytAFMxnPOM1DjDcflV9kHOOlVynzYH50AQ7ST3FMljDqwYD2q9GmAf61C4VmxzmgDnrm0CN061FDCytk4GPSt2SIyE5GAtUWgZGoAhMQcDcBUBgG8kdB0q8FBIBOWpwiB/A0AZklrHJgunOOtUb7SkkjGSzKOB/s10TQk8gdKZ5We2KAONjsLiAnDNsHQ9akgW7cOwVfl55OM/hXXLaKByOtRy6akjEY69xxQBxpvHDkMCGzg5rZ0q+KupD/rVi70DzCV2HaTkNnmqkGiXVv8AdIbHQE4oA7q0Es8e5W3IPQ1rQQKVG9xyOM1wVjqF9p0mHjkx371vWviu0kGy44PuMYoA0rmGNJhGQvPTHNWrJIorXdI7AMcACsQ6nBO2Ym69DnpQurE3Ox9pjUYA9D60AT6jbGOV2ic5JJx2Irn72JicNlCa6qTUreZQHCkr6Cs/VEt7yAtGwVgO3FAHN2k5imMbsxKnBPtXTadqXkPFJEocxHcA1cPqWYZAd3Oc5B61JY6oY8hwTuGOKAPadKig1q3N3aXUsUndQeQfTFX7KO2ilZHuCZPVjya8fsNcn04rLay7WzyvY08eLZrnUVPyq2ecDrQB63a3a6fqDxyMr+Z8yEHORzUurXkc8LxTcoV4GK80/tiW51CFjwkK4LCl1XxgkZ2q24gYBoAztes47O5cwk+WSeCOnNM0bWZbcmF2PlMfXpWXfa1Jeb2kUlT61iHUgGwgOfegD0hI1hl+1MVcjkKe9XzqjXCAqMAnnBrhrDUnubdcMxbptratLiRcZXAxQBsy3BL9OR0rM1zU7a2gwo3T8c+lMvLgAb9+09q4/V+XZjLu980AbFnq0ZR3uZTtHQVz2saubpyqEiEVi3NyXJVDn2qFIpHQM5CjsKAJrq+LfJFkL0qGGMHsSfWo5U4yv5+lFuSSOeMYoAvgbIwwwQKru5LvlCc8dOlThHCYi3FO+al2wkjltxHIJoAzQC0xCjBqbyiergd6kaIxMXDK2TwPSmsxOAFxjjigD3HhiOwpQAF9aSNgfapOMg0AREAKciq+wbj2arUnOah2/Mc84oAYPu/MTnNRn5WJFTyKCAeOaicfJx2oAgcO68DBFVdjMcN0NXl+9yScUGIE5I5z2oAoPAEfigRflWjJGGUZ6imbAAOM0AVtnykdKekOBnH41Z8sFvl/GpxECNvNAFQRDIzzmrC2Sng9T3qaKHac9QelWAoH17UAVEs3H3TkA4waetiJeGUr74rRjQ4AA9zV6CLIxg9KAOflsN8eGCsB3PWsy58PxT9YgfcCu/Wx3rtPOacdO28RjGKAPJ5tCWGbbGWTjqDiqsukmM/I8u7616rcaczSA4GcelVJrAYJCg4HUigDyua1uYmBSeT3FNaW+jQ7ZAQexFd5dWiM5JjHuQKy7jT0IPyHHagDz66jupmJcg5qLypo+Mfjmuyn05Fc5Uiqz2ERA7UAcp5jofmDmnW10sE/mbWz7it2WxBk2pUJ047uVHFAGU+qTuxVHKKfepLOO33b7mbc2elaY0zK5wtOXSN2Pu5oAa9/aRxGNdpzx0rmrpU84mM5Gc8VvzaWQ5GAcelV30/ZyMflQBRsdU+ygjBP4Vch8Syo5yrMuOmKb9hXuDn6U8WIXqAaAKtzqt1dtx8oNVHikkI81iSccVptGsTZ2/N6USMlvHtQeZcsMk9l9qAKf2VLTbu27iM9aS+ilxgAMhAIIPY1I9m8uyeQ5JPSrVxbsI1SPj1HagDCASNXL56YqWF0aUb8oNvGBVyLTmyrbec9SK0YdE8xl8zJIx+AoAz4Jj5ARgMY6jvVUqfNYbCTjgiutg0qOFMbSc/jSvpyZ3bcUAck9vJLn5ecd6dBYSZJcjGMcGumFmI/vAexzVkW6x5UYf3WgDulIU57H2pzsOvapJVypIGDVeYFlAPUd6AHOdx45z0ppUgKD160sS7W61MwDH5uooArsATyMH0pgQEcA5qw6YHHWoh29e9AELKF5UcnqalXPy47nmnFSOQDzT4gGVh2HNAEcq54PFQouTx26VZkTeQVPanJEpbJ/KgBkUQAyc5qULk8VMqKUI5zRGgUllBBH6UAOEfykCpoYg7dOAM49cU2JW3HcTjvV61jyW7YGKAIoozuOBxWpYKPtCLycDmmW8H7wAAY962tEgTy3LnazHFAFiGEE/Lj157USIFyD0x2rUFgVVWXhTk56/pUckWCRkMCOcCgDFCA5welUtQhIAVcEvyfwrZSJfOckfKq9R2qtJ+8dixB29PagDmri1UZLD3rKvIAuAF6iumuR+/Yrgrisu7QenQ0AcxdQAjBGDWbPbAk7gOPSuivY8knp3xWTKhKnGT70AYEkK7zywA96cYunUk1faMEnPapIbcOcngUAZ6254yOamjg2kHHNaIiVOe1QuuTuBNAFK5s5EQSFCEfofU1T8gkk44Najc/eJyKgmIGQeB7UAZjwrz6CqFy4jBKnIFXruQKNqtj1NU4bU3UvzZEQ6D196AKVvFJdNuUFQTwa0U09IwBt4PJJ6mtZLeKOMDBGPSngbh0OOnNAGTFYLIv7tSNp71aj08M3zD5a14IAFHBwalmVY+EGWHfsKAKEdrHGNu0etSjaI+eD2ocsMZOSTzUWc559qAHeYqqQTnjtUMgdwDj5fah43fhBk1bjjeOEJgHPPNAFIqpUofmP0qaG1O3GMDtipxCpkLEZPt2qeMlBjnNAHVzQEgY696gmh2Jz+dbBUiTGeSMiqV6SAqsAaAMzbgg9aUsQMsBk1KF7gDFN+UnnNADFO7Apsgw5qVFIJPr0prYOM9aAISTzjPpT4ySpXGCetOVSQMHvV1LeNkDAfMO+aAKKKV6dacFwRwetTzw4kTyz1HNKyhCozigBsYIYjv61KFdRxg5pYyoPOcmrKKsjZ9BigBsfmbQWWrVvnGSpyTRGhK9M471ftYSCmRgH1oAfaxk5LcHHWt22XYqk4II7iqtuqJ/rEyBU8MysUPVV4Kng0AacTqZPv8A/AatTzRBDGF+QDHBz83tWVJISclVPGODVeadhJlMjOMjrmgDQuRFHEcISxXnB/nWM+xYd2MkDt1qVr0jK8lsenr/APqrPlmLpiPns1AEEjgKXwee1ZzsDnJ6VbuCQ5QjaD1x6VlXUrKwXaeeAaAIL4b+3BNZ1whztAPAxWnKPLJL5JI4qpMCoUkjd6elAGY0IQbTyT19qlRFUYA6VLIBzkcnnNV85yOtADHQEg55HUVAy9TjAFWXGACRg1Vum29c4oAhlxgmsu8uETqcE/pVm5m2xtggKOp7VkbDdShnwIgeB60ARxQm7k3MD5YPAPf3rUhTyxgDpxTkUKu1KnjXAOBQAwBlPzg4PQVPHGV4PJpY/mcFjggcVMzBR1BagBS4jTGcmoGfceTTWYs3OMUjDjjvQAx2G3vmmQ4DBWGTTn6AcelT2sIYF3xwe9AF17X7OxRsBxjqc9vaoxCXYBuR1qXYQxyoI7VNEoD/ADHOR2oAiWAchRz70427O3DAe5qdHUkpjvz70jkxtgAhfUc0AdZOp2b8HI6VCFW5hViCM9Ce1W/MVx8/TuKzWf7LdENzG547YP8AnNAEdxEdxVY8H1qD7O5XOPwrRZg4DI3TIPNM34XGeCcUAZyRnfhuBSyogHB59qdNOqFRtO7pxTVUkgscHrigBkQdlKgfLnJNWUJTGT2ppPlnrx6UrkDpycUAJI5bnOKj5Y8859aRpFI3MKRJMn5eMetAEsYKjaV4z972qzHtC4ViM4zVbzCRhhknrUSzMrDkA/0oA3beZQUU9Cea14Jo9yjgHOeTxiuOt7rY7bq17W4SSISZJwQMGgDqEljGPMVWGTx2xUkwgKMQeRjp3rEguwoznPOcGpnvkfGUBGPXFAFplIBKkkkZ5NMLugBLD6Vn3GoASbU+7j8qgW9Bfghj+dAGhPO4uWGRuAGT36VWimInZQAF+9n1rO+0A72JyzE/jTVkZgSeOKALs02ZGAPBNU5G+Y8Diq8txtI+bHbFU3uCSSWPHagC3cuNoLkEg9Pas95VLknqeaguJhL8np396qTuynrnFAFqVtyZHQ1WLhM56elEMjNHjnHeoHYLIMfrQBM8hZMkgjt7VnXkuVOcAVZmlVUYscdyKwZ7gTiQEZDAqoz0OOtAEMu+6lEfSNfvY7mrscCoAMUy0j8tMAcDr71aRtxyOtACxoNpPrUwYKOmahaQbcDg1GjknPNAFpSG5xTXJ6gUx29P0oZyRgcCgCO4baeTzQGBwAcZqvcneuBnIPJq1a27SIG3DC9frQBNGqkFQQSD1q1aoyykY3KeuKrxxBWyucEc49av2iFEbn7x70ASI0e07OTnBFTKAmW24B6VJHBGsSOQMgnp3p5i3RkgnPQA0AMjTLEqMDHepQgVfmGaZau5ZkyAelSoGV2B6A4HOaANUXAXIPJ/U1DeOZ7WVeRjk/UVipczPFveNgAcg9iPWpre8VgxLAZ7UALYSXAiYhW8oMFLdgTnH8jV6VyseCeSc5rKa4VZMDgE5xnrUtzMzxNt25UevP4UATHHB7+tTLtKKFHzZ5NZVhK91n7y44Ge9WhJJbgZXOTigCS8cpKBkfSq3mMM7ScGmXUwaXAwDUBl296ALgbkDJ5p7yKAQox681UVzkE96JCSeKALKyn3zUTSc9Kg80g9aYXZjxQBYMuMse1XrK4AQsqkjrWLJG8i4yRV+2BjhCKeg/OgC3LqTKMsjDJxx2FPa78xRgnHc5rPZSxyOcdqrTJLEzGNyAeSO1AGm16TMiDpzmrENyOgGB7VzUlxOr9AQDy1X4bgFVwfqKANcyfIAvUVE1w4OB2HWqK3IBOWwe9QtccnJPNAFqW45OTVR7g4PPJ6etQSyFicngVUMvzbu9AGgZQqc9ap3F0qJliarNOW78H1qCfbIBuNAGlbXBaPK8Bu/tUbyjazEnriqiyBI9isKq3Fw0jCKIpvIIySB0570AQ6rf7f3cQ3MeBzTbKIqm9/vGqkSK8+8gZA2ggY3DPU+9aMI3LkHOO1AE8b8cjilLEng4FQGQZxml5GB1zQBMBlsd6ftJOF6d6YnUDrU8akEg4/CgAK7cY5pDwvPQ1N5XfnpmkVVZfvcAHgjNAESQCWRlHDAcL/AHq6XQtGjfT2kupvLDqWUdOaw7WGNp4W3OzNwcDp2rc1a5jmihitmDLGcZFAGYIxHKo5PP8A+urojBUhlB7jJqtINrgk++fWpUkLurKCMdc0AaMABtU+TbwefrRCGKyLv3FBu6dqWM/IBncnX8adbsBIT0Zu/wDSgBlvsZHkwQB6jnNTxoJkXa4V+SR6UkyFm+RsAcEVreF7RHluJJ8FQAvI5J9aAKlxaCfR0QDB25A9DXJtDcRvhY3c9yB3rqrXUEnjIR8lDtNL5qEEqAOM0AczY293PcjzLZ0jHJLV0U0VvHDu2qMDnPamzX0NrGzSyBMDp3NcpfahcalKSQY4c/Kg7j3oA6O1e2ebEMylhzx3o1hlgsGcOobtuOM1zLRgx5DtDMg42n73+FUjHI7A3NxJLt6KzZAoAuecd252684NWY3DAGqKDdktjNWI5ORx09KALqlsZbimFyuctxUQlyDz16c0xi+cEcdetAFiKVQTk5pxmG046561TU/PjpQwJGc0AW0mAPSphMME5/Ks1M9RzUiSY4HWgC8J8cjPNNkk+XGOPWqZmAJ3HH9aY0wzxzQBYk2umBwah+Ze+DUDzEZOAOaa1wccnJoAs+YV75qI3BDc/rUBlBTJPNQSTLhtxO49MUAWZpvl69TVVpsLgdaqySgDr1qvLOo6H60AXTMCeW5qJ58YANZbXPPUVDJdYGSaALlzebMndiqUJe5mEj/c/hFU0LXUpJzsHX3rVtwFGMYHTFAFuMYFSROEUhO5z1pkYz15ocgMBwO2aAHgk8hRkGrCEkcenWqYPUCrEOduOmKALttgkkdcd6ni4kyw4qC2TCZPPOKuRx4HBoAsTDauSeOozUUY3LhVHqaWRwwHOQoyOaImDOCWxnrzQA5lMbB4AyyKeSRxSxK5hO9CvU/WrEhG4HOT0qGeRtmBzQBWjuczCI5Pp6VbDv8AIQxVM8k+lVkhDOpDbOcHFacaKYirLwOvoaAL8QRE+Vy+V4PpTtiKgIGWPzde9VUZUwE6MPwFSwyttGdhOcA0AWklcyKJEATGc5rptEjKaerRRgiQlufyrkFk8xZA7YZRwB0Ndbpktxa2FvEoIwgPT15oA8us3ntXLocZ65q7JqriPGAG6VRk/wBb+NV7vqaAJbi4WRsyOWPXnmoGuBn5Bkk+vFVT1NSx9R9aAJHZ2IySPxp0I3Hoc+lK/WP611vgb/Xw/X+tAFDR/Deraqypp+n3ExY4BCHH59K77w/8GtbvZFbUjHYw5+bLbm/IV7v4T/5BUf0FbJ60Aea6L8HfD1iN17598/8AtttX8h/jVbV/grolyxfT7q5s2OflOHX9a9UooA+cNZ+CuuWjM+nywXqZ4AO1v1rmL34deKrTJl0i4ZR3TDfyr61PSl9KAPiC/sL6xlMd1bT27DtIhU1TJZZK+q/ir/yDm/3f6ivmbWf+P5v90fzoAymJY9eneo/MZSck0r/fNMoAJJD+FR+buXI+lK/3hUf8NADZJsHA5NV5J+wPNB++1QSdaAElmGAAaoTTHp79afN3qm/agAaXtnn1qq8jTyrGnQHk0H77fSn2H32oA0LZCqgRjA6GtCIHAB61Xs/u1cj/AIqAJEwp5JxQQWJ44qNu9Tw/c/CgAjTCgY/OpYzlgAMc96ROop4/14oA0oV2J696sqcN6A9Kan3R9KD95aAIsb2IB/WgfKpUUJ98/jTh940AXYyroD37UOVKnnmq8XUU8feNAAobCgfdHNWYJnO/pjB79v8AGo1/1Z+lR2/Rv900ATQSq3DcsDkdjUouURlx2PGao3P/AB+/8DH8qbcf6wfWgDVuCHVRG4Vj3Fd2qTzadbi2lYOowwzjtXnsX+qH413um/dH+6KAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_34_41519=[""].join("\n");
var outline_f40_34_41519=null;
